Epigenetic remodelling licences adult cholangiocytes for organoid formation and liver regeneration

Luigi Aloia*[1,2,3], Mikel Alexander McKie*[1,2,3], Grégoire Vernaz*[1,4,5], Lucía Cordero-Espinoza[1,2,3], Niya Aleksieva[6], Jelle van den Ameele[1,2], Francesco Antonica[2], Berta Font-Cunill[1,2,3], Alexander Raven[6], Riccardo Aiese Cigliano[7], German Belenguer[1,8], Richard L. Mort[9], Andrea H. Brand[1,2], Magdalena Zernicka-Goetz[2], Stuart J. Forbes[6], Eric A. Miska[1,4,5] and Meritxell Huch[1,2,3,8 $]

[1]The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, CB2 1QN, UK.

[2]Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3DY, UK.

[3]Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QR, UK.

[4]Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK

[5]Wellcome Sanger Institute, Hinxton, CB10 1SA, UK

[6]MRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK

[7]Sequentia Biotech SL, Calle Comte D'Urgell 240, Barcelona, Spain

[8] Max Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstraße 108, 01307 Dresden, Germany

[9]Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster, UK

* these authors contributed equally

$ **corresponding author:**

Meritxell Huch

m.huch@gurdon.cam.ac.uk;

and

huch@mpi-cbg.de

Abstract

Upon severe or chronic liver injury, adult ductal cells (cholangiocytes) contribute to regeneration by restoring both hepatocytes and cholangiocytes. Recently, we showed that ductal cells clonally expand as self-renewing liver organoids that retain their differentiation capacity into both hepatocytes and ductal cells. However, the molecular mechanisms by which adult ductal-committed cells acquire cellular plasticity, initiate organoids and regenerate the damaged tissue remain largely unknown.

Here, we describe that, during organoid initiation and *in vivo* following tissue damage, ductal cells undergo a transient, genome-wide, remodelling of their transcriptome and epigenome. TET1-mediated hydroxymethylation licences differentiated ductal cells to initiate organoids and activate the regenerative programme through the transcriptional regulation of stem-cell genes and regenerative pathways including the YAP/Hippo.

Our results argue in favour of the remodelling of genomic methylome/hydroxymethylome landscapes as a general mechanism by which differentiated cells exit a committed state in response to tissue damage.

The adult liver exhibits low physiological turnover, however it has an efficient regenerative ability following damage. Upon tissue injury, if hepatocyte proliferation is compromised, resident, lineage-restricted ductal cells (cholangiocytes) acquire cellular plasticity to regenerate both, cholangiocytes and hepatocytes[1-9]. Similarly, *in vitro*, ductal cells grown as clonal organoids become bi-potential, express stem/progenitor markers, including *Lgr5*[4,10,11], *Foxl1*[7] and *Trop2*[12], and differentiate into both ductal and hepatocyte-like cells *in vitro* and mature hepatocytes *in vivo,* upon transplantation[4,13,14]. However, the molecular mechanisms by which adult committed cells exit their lineage-restricted state, initiate proliferating organoids and respond to damage by generating both ductal cells and hepatocytes remain largely unknown.

During development, epigenetic mechanisms are imposed to ensure that differentiated cells remain lineage-restricted[15]. In mammals, 5-methylcytosine (5mC) is the most common DNA modification and is associated to gene repression at promoter and enhancer level[16-20]. DNA demethylation might occur passively, due to loss of DNA methylation maintenance during replication or via the conversion of 5mC to 5hmC by the Ten-eleven translocation (TET) family of methylcytosine dioxygenase enzymes[21,22], which results in dilution of 5hmC through DNA replication[23]. Moreover, cytosine demethylation can be achieved by a replication-independent mechanism mediated by TETs, whereby 5mC is converted to 5hmC, which can be further oxidized and replaced with an unmodified cytosine[24,25].

Erasure of 5mC and TET1 activity are essential for resetting the genome for pluripotency, germ-cell specification, imprinting and somatic cell reprogramming[26-30]. During development and postnatal life, *Tet1* is essential to maintain the intestinal stem cell pool[31]*,* while *Tet2* and *Tet3* are required to induce postnatal demethylation in hepatocytes[32]. However, whether epigenetic mechanisms and/or DNA-methylation/hydroxymethylation play a role in the acquisition of cellular plasticity in adult differentiated cells during the regenerative response has not been investigated yet.

Here, we report that in the liver, during the response to tissue damage, adult resident ductal cells undergo a genome-wide remodelling of their transcriptional and methylome/hydroxymethylome landscapes in the absence of ectopic genetic manipulation. We identify TET1-mediated hydroxymethylation and its downstream

84   regulation of ErbB/MAPK and YAP/Hippo signalling pathways as one of the

85   epigenetic mechanisms required for lineage-restricted ductal cells to acquire cellular

86   plasticity, establish liver organoids and elicit a full regenerative response.

87

Results

Adult non-proliferative ductal cells undergo genome-wide changes in their transcriptional landscape during organoid initiation and as a response to tissue damage

We recently reported a liver organoid culture system that allows the clonal and long-term expansion of mouse[4] and human[13] liver ductal cells as self-renewing bi-potent organoids capable of differentiating into ductal and hepatocyte-like cells *in vitro* and *in vivo*[4,13,14,33,34]. Using the pan-ductal marker EpCAM after excluding hematopoietic and endothelial cells (see methods) we isolated pure populations of ductal cells capable of generating organoid cultures from undamaged liver with ~15% efficiency (Extended Data Figure 1a). To confirm that organoid formation is not due to a subpopulation of proliferating ductal cells, we isolated EpCAM$^+$ cells from *R26Fucci2a* mice[35] and tracked their cell cycle dynamics. As reported[36], we found that virtually all EpCAM$^+$ ductal cells are arrested in G1/G0 (mCherry$^+$/mVenus$^-$/EpCAM$^+$) (Figure 1a-b and Extended Data Figure 1b), indicating that the organoid initiating cells are non-proliferative (Figure 1c). To investigate the molecular basis that endows adult committed ductal cells to initiate bi-potent organoids, we first estimated the time required for the cells to enter the S/G2/M phase. We found that first entry into S-phase takes ~40h from isolation, while subsequent G1 phases shortened to ~15h (Figure 1d-e, Extended Data Figure 1c and Movie 1).

Next, we performed genome-wide gene expression analysis (RNA-sequencing) in cells isolated directly from the undamaged tissue (0h), cells collected prior to entry in S-phase (12h and 24h) and after proliferation initiation (48h and organoid stage, 6 days). We found that adult differentiated ductal cells undergo profound transcriptional changes during the initiation and formation of organoid cultures. We identified >3,000 genes differentially expressed (DE) during the first 24h, prior to S-phase, while 900 genes changed after proliferation started (48h *vs* organoids) indicating that most of the organoid transcriptional signature is established within 48h in culture (Figure 2a-b, Extended Data Figure 2a and Supplementary Dataset 1).

We classified the differentially expressed genes into 10 clusters. Genes in cluster 3 and 7 (increased expression from 48h-onwards), were mainly enriched in cell-cycle, while genes in cluster 5, whose expression precedes the onset of proliferation (starts at 12h and peaks at 24h), were significantly enriched for chromatin regulators (Figure

5

122 2b-c). Of note, 55% (383 out of 698) of the genes from an epigenetic modifiers' list[37]

123 were differentially expressed, including Polycomb, SWI/SNF members and TETs,

124 while some ductal markers were transiently down-regulated (Figure 2d-e and

125 Extended Data Figure 2b). These results suggested that epigenetic mechanisms might

126 be prominently involved in the initiation of liver organoids from non-proliferative,

127 lineage-restricted ductal cells.

128 Organoids mimic many aspects of the tissue-of-origin in a dish[38], however, they have

129 not been used to study the molecular mechanisms of tissue regeneration. Therefore,

130 we opted to benchmark our organoid cultures to the *in vivo* response to tissue damage

131 by studying the transcriptional changes that occur *in vivo* after injury and compare

132 these to our organoid findings. For that, we induced liver damage to adult mice by

133 administering a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)

134 supplemented diet (Figure 2f). Proliferation initiation began at day 3 (d3) and peaked

135 at day 5 (d5) of damage (Figure 2g). Interestingly, also *in vivo*, ductal cells undergo

136 significant genome-wide changes of their transcriptional landscape, with >1,500

137 genes differentially expressed between the undamaged and any of the two damage

138 time points (Supplementary Dataset 1 and Extended Data Figure 2c-e). Notably, most

139 of the transcriptional changes occur at d3, before the significant increase of

140 proliferation, resembling our *in vitro* observations.

141 Interestingly, 71.4% of the DE genes *in vivo* were also found as DE genes *in vitro*

142 (1,108 out of 1,552 genes) and presented similar expression patterns. Specifically,

143 epigenetic regulators such as *Tet1, Hdac7, Uhrf1 or Dnmt1,* hepatoblast markers

144 (*Foxa3, Sox4)* or ductal markers presented similar patterns (Figure 2h-i and Extended

145 Data Figure 3a).

146 Altogether, these results reveal that both, *in vivo* and *in vitro*, ductal cells undergo a

147 global rewiring of their transcriptional landscape as a response to tissue damage, and

148 validate organoids as a model to study some molecular mechanistic aspects of tissue

149 regeneration.

150

151 **TET1 catalytic activity is required for organoid initiation and expansion**

152 To identify potential epigenetic regulators required for the activation of ductal cells

153 during organoid initiation, we selected some of the DE epigenetic modifiers during

154 the first 24h and assessed the effect of their loss-of-function (siRNA knock-down) on

155 organoid initiation. We found that depletion of *Tet1* significantly impaired organoid

156   formation, while *Tet2* knock-down exhibited a reduction, but was not statistically

157   significant (Figure 3a and Extended Data Figure 3b).

158   Thus, we further investigated the role of TET1 in organoid initiation and expansion.

159   For that, we generated 2 independent TET1 mutant alleles: (1) a conditional allele

160   (*Tet1$^{flx/flx}$*) enabling the spatiotemporal control of TET1 deletion and (2) a

161   hypomorphic allele (*Tet1^{hypo}*) which displays ~35% of *Tet1* mRNA and protein levels

162   (*Tet1$^{hypo/hypo}$*) compared to WT littermates (Extended Data Figure 3c-e and

163   Supplementary Table 1).

164   We found that ablation of TET1 in FACS-sorted ductal cells derived from

165   *Rosa^{CreERT2}/Tet1$^{flx/flx}$* abrogated organoid formation (Figure 3b), in agreement with the

166   siRNA results (see Figure 3a and Extended Data Figure 3b). In addition, TET1

167   depletion in established organoids impaired their expansion (Extended Data Figure

168   3f). Organoids generated from the *Tet1* hypomorphic mutant mice (*Tet1$^{hypo/hypo}$*)

169   exhibited reduced 5hmC levels and expansion defects, despite that they could be

170   established (Figure 3c-e and Extended Data Figure 3g-k). Organoids derived from

171   heterozygous or *WT* littermates displayed no growth defects (Extended Data Figure

172   3h-k). Importantly, ectopic expression of full-length TET1 cDNA (hypo-OE

173   organoids), but not a catalytically inactive mutant (TET1$^{H1671Y/D1673A}$)[29,39] (hypo-

174   OE$^{cat.mut.}$ organoids), rescued all these phenotypes (Figure 3c-e and Extended Data

175   Figure 3g/k). Altogether, these results demonstrated that the catalytic activity of TET1

176   is required to initiate and propagate liver organoids from lineage-restricted, non-

177   proliferative, ductal cells.

178

179   **Genome-wide changes in DNA methylation/hydroxymethylation occur during**

180   **the activation of ductal cells following damage**

181   Given the crucial role of TET1-mediated hydroxymethylation in organoid initiation,

182   we speculated that epigenetic regulation of DNA methylation and

183   hydroxymethylation levels could be involved in the ductal regenerative response to

184   damage *in vivo*. For that, we quantified the levels of DNA methylation at single base

185   resolution by Whole Genome Bisulfite Sequencing (WGBS) in genomic DNA

186   extracted from EpCAM^{+} ductal cells sorted from undamaged and d3 and d5 DDC-

187   damaged livers (Figure 4a, Extended Data Figure 4a-c, Supplementary Dataset 2).

188   WGBS revealed a global increase in cytosine modification (5mC and/or 5hmC) at d3

189   after damage, while d5 and undamaged controls showed similar global levels (Figure

190   4b) although modifications occurred in the same CpG only in ~50% of the cases

191   across the time points analysed (Extended Data Figure 4d). Next, we identified the

192   differential levels of cytosine modification in defined regions in a CpG context

193   (DMRs) (Extended Data Figure 4e-f). At d3, the majority of DMRs represented a gain

194   of modified cytosine (mCpG) compared to undamaged (68%) whereas at d5 and

195   between both damage time points, these were mainly associated with a loss in mCpG

196   (56%, and 75%, respectively) (Figure 4c and Extended Data Figure 4g). We then

197   analysed the levels of mCpG at the TSS (+/- 500bp) of genes transcriptionally up-

198   regulated after damage. From all up-regulated genes, 32.6% (337 out of 1032) showed

199   decreased methylation/hydroxymethylation levels at d3 (Figure 4d-e and Extended

200   Data Figure 4h), suggestive of a potential role of demethylation in their transcriptional

201   activation.

202   Of note, we also found that a significant proportion of all up-regulated genes (34%,

203   349 genes out of 1032) presented increased levels of mCpG (Figure 4f and Extended

204   Data Figure 4h). Since WGBS cannot discriminate between 5mC and 5hmC, we

205   hypothesized that this could be explained by an increased 5hmC. Hence, we

206   performed Reduced Representation of Hydroxymethylation Profiles (RRHP), to

207   identify 5hmC at single base resolution in the same DNA samples used for the WGBS

208   (see Figure 4a and Supplementary Dataset 2). Consistent to 5hmC

209   immunofluorescence stainings on ductal cells upon *in vivo* damage in *WT* mice or

210   upon β1 integrin deletion (a damage model of duct-mediated hepatocyte

211   regeneration[9]) and during organoid initiation (Extended Data Figure 5a-c), RRHP

212   showed increased 5hmC sites upon damage (Figure 4g and Extended Data Figure 5d).

213   To identify 5hmC regulated targets, we analysed 3,581 genes showing differential

214   hydroxymethylation levels i.e., presenting ≥4 unique 5hmC sites at their TSS, either

215   in undamaged or after damage. Of note, >95% of these genes (3,450 genes) had

216   acquired *de novo* 5hmC sites at d3, prior to proliferation, while most of these *de novo*

217   marks were lost at d5, suggestive of a significant transient reshaping of the

218   hydroxymethylome as a response to damage and prior to cell proliferation (Figure 4h-

219   j and Extended Data Figure 5e). Notably, 5hmC levels did not increase in CpG islands

220   (CGI) outside TSS (Extended Data Figure 5f).

221   The differentially hydroxymethylated genes could be classified in six clusters (1-6),

222   with clusters 2-4 presenting increased 5hmC at day 3 and reduced levels at day 5 and

223   cluster 6 (140 genes) showing overall increased 5hmC levels at day 5 (Figure 4j and

224 Extended Data Figure 5g). When overlapping genes with increased 5hmC with genes

225 differentially expressed *in vivo* we found 154 genes transcriptionally up-regulated

226 (Figure 4k and Supplementary Dataset 1). Interestingly, some of these also presented

227 increased cytosine modifications in the WGBS at d3, prior to proliferation, hence

228 explaining, at least in part, the observed dichotomy between the increased levels of

229 modified cytosine in the WGBS and the increase in transcription. Among these, we

230 found genes involved in liver regeneration signalling pathways (e.g. *Erbb2*)[40] and

231 liver development (*Foxa3, Sox4*)[41] (Figure 4l). In addition, 84 genes showing

232 differential 5hmC levels were also down-regulated *in vivo*, including negative

233 regulators of the BMP pathway (*Bambi*) and genes important for hepatocyte

234 differentiation (*Cebpa* and *Atf3)* (Extended Data Figure 5h and Supplementary

235 Dataset 1).

236 Altogether, our genome-wide analyses suggest that transient increase in

237 hydroxymethylation levels might facilitate the acquisition of cellular plasticity in

238 ductal cells and subsequent initiation of the response to damage.

239

240 **TET1 induces ductal cell plasticity through the regulation of the YAP/Hippo and**

241 **ErbB/MAPK signalling pathways**

242 Our findings indicate that hydroxymethylation levels rise upon damage in

243 genes/pathways relevant for liver regeneration, at the time where *Tet1* expression is

244 increased, and before the onset of proliferation. Therefore, we next sought to elucidate

245 TET1-regulated genes involved in the acquisition of cellular plasticity during liver

246 regeneration. Hence, we investigated TET1 genomic occupancy by performing

247 Targeted DamID-seq (DNA Adenine Methyltransferase IDentification

248 sequencing)[42,43] (Extended Data Figure 6a). We found 5,102 TET1 specific peaks,

249 56% of which were in actively transcribed regions (Extended Data Figure 6b-c and

250 Supplementary Dataset 3). We next identified TET1 targets by overlapping the peaks

251 to a +/-2Kb region around the TSS. We found 2,358 TET1 target genes in liver

252 organoids, 88% of which shared an H3K4me3 peak, indicating that TET1 binding at

253 TSS occurs mostly in transcriptionally active genes (Figure 5a). These were involved

254 in cell-cycle, transcription and chromatin organisation, among others (Extended Data

255 Figure 6d).

256 Notably, we identified TET1 binding on stem-cell genes such as *Lgr5*[10], *Axin2*[44,45]

257 and *Lrig1*[46], the known TET1-target *Cdk1*[47], epigenetic regulators (*Cbx3, Ezh2,*
258 *Dnmt1, Hdac1*) and liver development transcription factors (*Onecut1* and *Onecut2*)
259 (Figure 5b and Supplementary dataset 3). TET1 and 5hmC levels were increased
260 before transcription of the stem-cell genes *Lgr5, Trop2* and *Sulf2,* while both, *Lgr5*
261 mRNA and 5hmC were reduced in organoids with low levels of TET1 (TET1$^{hypo/hypo}$)
262 and could be rescued by ectopic expression of TET1 (Figure 5c and Extended Data
263 Figure 6e-g). TET1-dependent 5hmC might co-operate with the existing
264 transcriptional regulatory machinery, as the recruitment of TET1 to *Lgr5,* a TCF4
265 target[48], paralleled the binding of TCF4/*Tcf7l2* to the locus (Figure 5c). As expected,
266 no TET1 binding or changes in 5mC/5hmC were detected in genes not expressed,
267 including the hepatoblast marker *Afp* and hepatocyte marker *Alb* (Figure 5b and
268 Extended Data Figure 6g). Of note, some TET1 targets were also up-regulated *in vivo*
269 (see Figure 4, Extended Data Figure 4h and Supplementary Dataset 4). The overlap
270 between TET1 targets and DE genes *in vivo* and *in vitro* (see Figure 2h) suggests that
271 TET1 mainly functions as a transcriptional activator in liver ductal cells (Figure 5d
272 and Supplementary Dataset 1).
273 To further elucidate the mechanism by which TET1-mediated hydroxymethylation
274 regulate organoid formation and liver regeneration we performed KEGG pathway
275 enrichment analysis on TET1 targets that were also differentially hydroxymethylated
276 upon damage *in vivo*. This revealed a significant enrichment on several
277 components/targets of signalling pathways including mTOR, ErbB, MAPK and
278 YAP/Hippo, among others (Figure 6a, Supplementary Dataset 2).
279 Interestingly, mTOR, ErbB, MAPK and YAP/Hippo have been extensively described
280 to be essential for liver regeneration *in vivo*[40,49-53]. Additionally, YAP/Hippo and
281 mTOR have been recently identified as required for intestinal[54] and liver[50] organoid
282 expansion. Therefore, we hypothesized that the direct regulation of these pro-
283 regenerative pathways could explain the mechanism by which TET1 facilitates the
284 acquisition of cellular plasticity in liver ductal cells upon tissue injury or during
285 organoid initiation. We first validated TET1 occupancy by ChIP-qPCR on selected
286 TET1 targets [ErbB and MAPK (*Egfr, Foxo3, Socsc2, Jun*) and YAP/Hippo
287 (*Wwtr1/Taz, Tead1, Gadd45b and Ctgf*)] (Figure 6b). Next, we assessed whether their
288 expression was TET1 dependent, by evaluating their mRNA levels following TET1
289 depletion in *Rosa^{CreERT2}/Tet1$^{flx/flx}$* organoids. We found a consistent down-regulation
290 of YAP/Hippo pathway components such as *Wwtr1/Taz* and *Tead1* and target genes

291   such as *Gadd45b* and *Ctgf* upon TET1 knock-down (Figure 6c). The expression levels

292   of these, except for *Gadd45b*, were rescued in TET1 hypo-OE organoids (Figure 6d).

293   For several of the components and targets of the ErbB/MAPK pathways (*Egfr*, *Foxo3*,

294   *Jun*) we detected both, up- or down-regulation following TET1 knock-down (Figure

295   6c).

296   Thus, we evaluated whether TET1-dependent regulation of these pathways is

297   involved in the acquisition of cellular plasticity during organoid formation. We

298   confirmed TET1 binding to some of these targets at 18hrs after seeding (Figure 6e).

299   To elucidate whether ErbB, MAPK and YAP/Hippo signalling act down-stream of

300   TET1, we then supplemented the cultures with small molecule inhibitors of the

301   aforementioned pathways (Gefitinib (EGFRi), PD032509 (MEKi) and Verteporfin

302   (YAPi)) for the first 18h in culture (0-18hrs), i.e., before TET1 binding, and at 18hrs-

303   48hrs, i.e., after TET1 binding, and evaluated organoid formation efficiency 6 days

304   later. Treatment at 18-48hrs, once TET1 is bound to its targets, induced a significant

305   decrease of organoid formation, thus suggesting that the regulation of ErbB, MAPK

306   and YAP/Hippo signalling could represent one of the mechanisms by which TET1

307   positively regulates organoid formation from mature liver ductal cells (Figure 6f).

308   Conversely, treatment before TET1 binding (0-18h) or inhibition of FGFR1/3 did not

309   cause any significant effect on organoid formation (Figure 6f and Extended Data

310   Figure 7a). mTOR inhibition instead, resulted in ablation of organoid formation

311   regardless of the time of supplementation, suggesting that either this pathway is

312   essential during the first 18h for ductal cell survival *in vitro* or is not regulated by

313   TET1 (Extended Data Figure 7a). Thus, our results suggest that TET1 promotes the

314   acquisition of cellular plasticity in ductal cells, at least in part, via the regulation of

315   YAP/Hippo and ErbB, MAPK signalling pathways.

316

317   **TET1 is required for ductal-mediated hepatocyte and cholangiocyte**

318   **regeneration**

319   To elucidate whether TET1 is relevant for liver regeneration, we induced liver

320   damage to the *Tet1* hypomorphic and ductal specific *Tet1* mutant mice. As damage

321   paradigms, we opted for three different models: (1) acute damage with 5 days DDC

322   treatment; (2) chronic damage caused by repetitive doses of DDC and (3) a damage

323   model where hepatocyte proliferation is impaired by over-expression of p21 and

324   ductal cells have been demonstrated to regenerate both themselves and hepatocytes

325   [2,8,9] (Supplementary Table 1).

326   To address the role of TET1 during acute liver damage we used the TET1

327   hypomorphic allele *(Tet1^{hypo/hypo})*, since the conditional *Rosa^{CreERT2} /Tet1^{flx/flx}* exhibited

328   partial lethality upon Cre induction, in agreement with the published TET1 full KO[31]

329   (Supplementary Table 1). *Tet1^{hypo/hypo}* mice presented no obvious phenotype under

330   homeostasis (Extended Data Figure 8a-d). However, upon damage, it exhibited

331   significantly lower number of proliferating liver ductal cells (Ki67$^+$/OPN$^+$ cells) and

332   absolute number of liver ductal cells when compared to *WT* control littermates

333   (Figures 7a-b and Extended Data Figure 8e-h). Notably, this reduced proliferation of

334   the ductal compartment was not explained by differences in the extent of liver damage

335   between genotypes (Extended Data Figure 8b and d).

336   Interestingly, upon chronic liver damage, *Tet1^{hypo/hypo}* mice presented extended

337   fibrosis (Figure 7c-d). Since *Lgr5* depletion *in vivo* results in tissue fibrosis[55] we

338   evaluated the levels of *Lgr5* in our mutant mice and found reduced expression and

339   less hydroxymethylation of *Lgr5* loci in *Tet1^{hypo/hypo}* mice (Extended Data Figure 8i).

340   To discriminate whether the defects on liver regeneration observed were caused by

341   the lack of TET1 expression in the adult ductal compartment, we generated a ductal-

342   specific TET1 mutant mouse by crossing the *Tet1^{flx/flx}* allele with the ductal specific

343   driver *Prom1Cre^{ERT2}* (Extended Data Figure 9a and[56,57]). To visualise and trace

344   recombination events, we further combined this mouse with the *Rosa^{lslZsGreen}* reporter

345   to generate the *Prom1Cre^{ERT2}/Rosa^{lslZsGreen}/Tet1^{flx/flx}*, referred here as *Prom1^{ΔTet1/ZsGreen}*

346   in contrast to the TET1 WT, named here as *Prom1^{Tet1WT/ZsGreen}* mice. We confirmed

347   the reliability of the ZsGreen to reflect TET1 levels after recombination. No ZsGreen

348   induction was found without tamoxifen treatment (Extended Data Figure 9b-d).

349   To assess the role of TET1 in ductal-mediated liver regeneration, we used a recently

350   established liver damage model where hepatocyte proliferation is inhibited by p21-

351   over-expression[9] and fed the mice DDC for 3 weeks (Figure 8a and Extended Data

352   Figure 9e-f). We observed a massive expansion of ductal cells (OPN$^+$/ZsGreen$^+$) in

353   *Prom1^{Tet1WT/ZsGreen}* mice while *Prom1^{ΔTet1/ZsGreen}* mice exhibited a significant reduction

354   (Figure 8b-c), in agreement with our Tet1 hypomorphic model (see Figure 7a-b).

355   Notably, when we examined the contribution of TET1 depleted ductal cells to

356   hepatocyte regeneration, we observed a dramatic reduction in the size of hepatocyte

357   clusters in the $Prom1^{\Delta Tet1/ZsGreen}$ mice, with most clusters formed by 1-2 cells only,

358   while $Prom1^{Tet1WT/ZsGreen}$ mice readily generated hepatocyte clusters from 1 to 156

359   cells (Figure 8d-e).

360   Molecular analysis of TET1-null ductal cells upon damage indicated that also *in vivo*

361   TET1 binds to the TSS and regulates the expression of some genes from the pro-

362   regenerative YAP/Hippo and ErbB/MAPK signalling pathways (namely *Egfr*,

363   *Gadd45b*, *Wwtr1/Taz* and *Tead1)* (Extended Data Figure 9g-h), in line with our

364   organoid data (see Figure 6).

365   Altogether, our studies demonstrate that TET1 plays a crucial role in ductal-driven

366   liver regeneration, at least in part, through the direct activation of the YAP/Hippo and

367   ErbB/MAPK signalling pathways.

368

Discussion

Many adult epithelial tissues exhibit cellular plasticity not associated with unrelated fates, but with contribution to tissue repair (see[58] for extended details). Under homeostasis a unipotent population of hepatocytes maintain the tissue[45,59,60]. Following hepatocyte injury, the lost tissue is repaired by remaining hepatocytes[61]. However, upon severe or chronic liver damage, mature cholangiocytes activate a regenerative response to restore both themselves and hepatocytes[5,9,62,63]. Yet, the molecular mechanisms behind the activation of this cellular plasticity on liver resident ductal cells remain largely unknown. This knowledge is critical to understand human liver diseases characterized by prominent ductal proliferation and hepatic fibrosis[64,65]. Here we demonstrate that upon damage and during organoid formation resident ductal cells undergo genome-wide changes in their transcriptional landscape and a significant remodelling of their DNA methylome and hydroxymethylome. We identify demethylation and TET1-mediated hydroxymethylation as an epigenetic mechanism required for ductal cell activation *in vitro* and *in vivo,* after damage (Figure 8f). The acquisition of the cellular plasticity that endows differentiated ductal cells with regenerative capacity *in vivo*, might occur through a progenitor state, as our organoid data imply. However, whether *in vivo*, new cells are provided through a direct division of differentiated cells, via de-differentiation to a progenitor state, by direct trans-differentiation or a combination of all these[66], remains unknown and will require further and more extensive investigations.

Cancer cell lines and liver cancer, exhibit relatively low levels of 5hmC[67,68]. In contrast, our results, indicate that transient high levels of 5hmC are required to induce ductal cells to activate the regenerative program, similar to what has been reported in pluripotent cells[39]. TET enzymes have been shown to promote genome integrity in mouse ES cells[69]. Hence, it is tempting to speculate that transient *Tet1* induction during liver damage might be a mechanism for activating the regenerative program in ductal cells while preserving genome integrity in the regenerating cell.

Interestingly, our analyses indicate that the mechanism by which TET1 facilitates the acquisition of cellular plasticity and subsequent pro-regenerative effect is, at least in part, through the direct regulation of ErbB, MAPK and YAP/Hippo regenerative pathways[40,50-53]. Whether other genes transcriptionally activated/repressed by TET1 are involved in the process requires further investigations.

402   Notably, the rewiring of the transcriptome and DNA methylome and
403   hydroxymethylome occurs prior to proliferation, as a response to tissue damage and in
404   the absence of any ectopic genetic manipulation. This mechanism resembles
405   embryonic reprogramming, where genome-wide methylation erasure is essential to
406   reset the epigenome for pluripotency[28]. Our observations might represent a more
407   general mechanism by which adult committed cells initiate the regenerative response
408   to damage.
409

445

Author contributions

447 M.H. and L.A. conceived and designed the project and interpreted the results. L.A.,

448 M.A.M., L.C-E., G.B., G.V., N.A., J.v.d.A., A.R. and MH designed and performed

449 experiments and interpreted results.. L.A. designed and performed the *in vitro*

450 experiments, M.A.M., designed and performed the *in vivo* experiments, L.C-E., the

451 hydroxymethylation and EdU stainings, G.B, experiments with small molecule

452 inhibitors. G.V. and E.A.M. prepared and analysed WGBS and RRHP libraries,

453 analysed RNAseq and interpreted corresponding bionformatic analyses related. N.A.,

454 A.R. and S.J.F. performed experiments with β1 integrin model and interpreted results

455 of the p21 models. J.v.d.A. and A.H.B. performed DamID-seq experiments. B.F-C

456 helped on the *in vivo* analysis. R.A.C. helped on bioinformatics analyses. R.L.M.

457 provided the *R26Fucci2a* line. F.A. and M.Z.G. performed the live imaging of ductal

458 cells. L.A. and M.H. wrote the manuscript. All authors commented on the manuscript.

Author information

460 Authors declare no competing financial interests.

461

462
463 **Figure Legends:**

464

465 **Fig. 1: G1/G0 arrested liver ductal cells require ~48h to start cell proliferation**
466 **and initiate liver organoids cultures**
467 *R26Fucci2a* mice constitutively express a bi-cistronic cell-cycle reporter that allows
468 discriminating between G1/G0 [Cherry-hCdt1+ (30/120), red] and S/G2/M [Venus-
469 hGem+, (1/110) green] phases of the cell cycle. **a**, Experimental approach **b**, EpCAM$^+$
470 liver ductal cells from R26Fucci2a mice were FACS-sorted according to the
471 expression of mCherry-hCdt1 (C) and/or mVenus-hGem (V). The graph represents
472 percentage of EpCAM$^+$ cells positive for mCherry and/or mVenus. Each dot
473 represents an independent experiment from an independent mouse (n=3). Graph is
474 presented as mean±SD of 3 independent experiments. **c**, Representative bright field
475 images of 500 C$^+$/V$^-$ EpCAM$^+$ and C$^-$/V$^-$ EpCAM$^+$ cells cultured for 6 days as liver
476 organoids. The graph represents mean±SD of organoid formation efficiency (n=3
477 experiments). *p*-value was calculated using Student's two tailed t-test. ******,
478 *p*=0.001413095. **d,** Still images from a representative movie of C$^+$/V$^-$ EpCAM$^+$ ductal
479 cells monitored for 72h using a spinning-disk confocal microscope. Scale bars, 10μm.
480 **e**, Graph represents G0/G1 length for the first (I) and second (II) cell cycles since
481 t=0h (isolation) of n=34 cells, pooled from 3 independent experiments). Global mean

482 of G0/G1 length is shown (G0/G1 I = 37.97 h, hours; G0/G1 II = 10.20 h, hours). **h,**
483 hours.
484
485 **Fig. 2: Liver ductal cells undergo genome-wide changes in their transcriptional**
486 **landscape during organoid initiation and *in vivo* upon damage**
487 **a-e,** Expression analysis of ductal cells during organoid initiation. **a,** Experimental
488 Scheme. Graph represents DE genes (pairwise approach with Wald test performed
489 using Sleuth. Threshold FDR <0.1) **b**, Hierarchical clustering of all 7580 DE genes.
490 Heatmap represents averaged TPM values of biological replicates scaled per gene (Z-
491 score). Number in bold, cluster. n, number of genes/cluster. **c,** GO and statistical
492 analyses were performed using DAVID 6.8. Red, cluster containing DE genes at 12h
493 and 24h. **d,** Heatmaps representing averaged Z-score of indicated genes. **e,** Graphs
494 represent mean±SD of n=6 independent RT-qPCR experiments. Independent
495 experimental data are listed in Source Data. Data are presented as fold-change
496 compared to t=0h. *p*-value is calculated using two-way ANOVA combined with
497 Tukey HSD test. *p*-value of comparisons *vs* t=0 are shown. **, $p<0.01$; ***, $p<0.001$.
498 Exact *p-values* are provided in Source Data. **f-i,** Expression analysis of ductal cells
499 following liver damage by supplementing the diet with 0.1% DDC (see methods). **f,**
500 Experimental scheme. **g,** Immunofluorescence analysis of ductal cell proliferation
501 upon damage. Representative images are shown (3 experiments). Scale bar, 50μm.
502 Graph represents mean±SD of proliferating ductal cells (undamaged n=3 mice, DDC
503 d2 n=3 mice, d3 n=4 mice, d5 n=4 mice). *p*-values were calculated *vs* undamaged
504 using pairwise comparisons with Wilcoxon rank sum test (DDC d3 p= 0.01201; DDC
505 d5 p= $7.6E^{-05}$). *, $p<0.05$; ***, $p<0.001$. **h,** RNA sequencing analysis of sorted
506 EpCAM$^+$ ductal cells isolated from undamaged or DDC-treated livers (2 livers have
507 been assessed per time point). Venn diagram, overlap between DE genes *in vitro* and
508 *in vivo*. *p*-value is calculated using normal approximation of the hypergeometric
509 probability. Table indicates the GO analysis (top 3 significant categories) of the 7
510 clusters identified in **i** (Cluster 1 n=183; Cluster 2 n=276; Cluster 3 n=260; Cluster 4
511 n=69; Cluster 5 n= 76; Cluster 6 n= 154; Cluster 7 n=90) and their p-values obtained
512 with DAVID 6.8. **i,** Heatmap (averaged Z score) of the hierarchical clustering of the
513 1108 DE genes based on the *in vitro* expression profile. Number in bold, cluster. n,
514 number of genes/cluster.
515
516 **Fig. 3: TET1 catalytic activity is required for liver organoid initiation and**
517 **maintenance**
518 **a,** FACS-sorted EpCAM$^+$ ductal cells freshly isolated from WT undamaged livers
519 were transfected with a pool of siRNAs, each of them targeting specifically a selected
520 epigenetic modifier, and organoid formation efficiency was evaluated 10 days later.
521 Results are shown as percentage of organoid formation efficiency compared to mock
522 transfected cells. The graph represents mean±SD of n=3 independent experiments
523 (dots). *p*-values were calculated using one-way ANOVA in conjunction with Tukey's
524 HSD test by comparison to siCtrl. *, *p*= 0.01031057 siTet1 *vs* siCtrl,. **b,** FACS-sorted
525 EpCAM$^+$ ductal cells derived from *RosaCreERT2 x Tet1$^{flx/flx}$* mouse livers were plated
526 in organoid isolation medium supplemented with 5μM hydroxytamoxifen or vehicle
527 and organoid formation efficiency was evaluated 6 days later. Representative bright
528 field images are shown. Data are reported as percentage of organoid formation
529 compared to Cre$^-$Tam$^-$ cells. Graphs represent mean±SD of n=3 independent
530 experiments. *p*-value was calculated using Student's two-tailed t-test *vs* Cre$^-$Tam$^-$ (*,
531 Cre$^-$Tam$^+$ *p*=0.03781815; ***, Cre$^+$Tam$^+$ *p*=4.812E^{-05}). **c-e,** EpCAM$^+$ ductal cells

532 isolated from Tet1 hypomorphic mice were used to generate liver organoids
533 (*Tet1$^{hypo/hypo}$*, blue) or were transfected with a hTET1 full length cDNA (hypo-OE
534 organoids, red) or catalytically inactive hTET1 H1671Y/D1673A (hypo-OEcat.mut.
535 organoids, turquoise). Organoids derived from WT littermates were used as controls
536 (black). **c,** Scheme indicates the lines generated. **d,** Western blot analysis of TET1
537 protein levels. The graph represents TET1 levels. Complete blot is shown in data
538 source. Results are presented as mean±SD of n=3 independent experiments (dot). **,
539 *p*-value calculated using Student's two-tailed t-test vs WT (*Tet1$^{hypo/hypo}$*
540 *p*=0.006779543). **e,** Representative bright field images of *WT* (2 line), *Tet1$^{hypo/hypo}$*(4
541 line) hypo-OE (1 line) and hypo-OEcat.mut. (1 line) organoid lines at passage 3.
542 Graph indicates passage number.
543
544 **Fig. 4: Liver ductal cells undergo global remodelling of DNA methylation and**
545 **hydroxymethylation landscapes *in vivo* upon damage**
546 **a-l,** gDNA from undamaged or DDC-damaged livers was split in two fractions and
547 prepared for WGBS (**a-f**) or RRHP (**g-l**) (2 mice per time point). **a,** Experimental
548 design. **b,** Graph shows the percentage of modified CpG (mCpG) sites according to
549 different level categories (average of replicates). **c,** Number of differentially
550 methylated/hydroxymethylated regions (DMRs) present in the n=2 biological
551 replicates. DMR were called based on a modification difference ≥25%, p<0.05 (see
552 methods). **d-e,** Graphs (mean±95%CI) represent percentage of modified cytosines at
553 TSS for all n=337 up-regulated genes (**d**) or selected ones (**e**) showing decreased
554 mCpG levels at d3 (average of replicates). *p*-value was obtained by Kruskal Wallis
555 test with Dunns multiple comparison. ****, undamaged *vs* d3 p<0.0001, ***,
556 undamaged *vs* d5 *p*=0.0003, d3 *vs* d5 *p*=0.0004. TET1 targets (see Figure 5) are
557 represented in bold red. **f,** Graph represents all n=349 up-regulated genes after
558 damage presenting increased mCpG level at TSS (mean ±95% CI). *p*-value was
559 obtained by Kruskal Wallis test with Dunns multiple comparison. ****, undamaged
560 *vs* d3 p<0.0001, undamaged *vs* d5 p=0.3773, d3 *vs* d5 p<0.0001. **g,** Distribution of
561 total 5hmC sites identified. **h,** Number of genes showing ≥4 5hmC sites around their
562 TSS. **i,** Graph represents median±IQR of 5hmC counts from the n=3581 genes
563 differentially hydroxymethylated. *p*-value was obtained using Kruskal Wallis test
564 coupled with Dunn's multiple comparison. All p-values are <0.0001. ****, p<0.0001
565 **j,** The heatmap represents the z-score values of 5hmC absolute count. 5hmC levels
566 were classified into 6 clusters. n, number of genes/cluster. Graphs (median±IQR)
567 represent the number of 5hmC counts of differentially hydroxymethylated genes. *p*-
568 value was obtained by Kruskal Wallis test with Dunns multiple comparison. All p-
569 values correspond to p<0.0001 (****), except for ***, *p*=0.0009. **k,** Heatmap
570 represents Z-score of the 154 overlapping genes. **l,** Graph represents the levels of
571 mCpG from the 154 genes identified in **k** averaged for the 2 biological replicates. In
572 **k-l,** TET1 targets (see Figure 5) are represented in bold red.
573
574 **Fig. 5: TET1 regulates the activation of genes involved in organoid formation**
575 **and liver regeneration**
576 **a-b,** TET1-DamID analyses were performed in 3 independent experiments. **a,**
577 Heatmaps of TET1-DamID (left) and H3K4me3 (right) binding at the TSS Venn
578 diagram indicates the overlap between the DamID-seq TET1 and H3K4me3 target
579 genes identified by ChIP-seq. **b,** Genome tracks of TET1 (Dam-ID) and H3K4me3
580 (ChIP) peaks on selected genes. Graphs show TET1-Dam/Dam only ratio (blue) and
581 H3K4me3 number of reads (green). **c,** Sorted EpCAM[+] cells from WT undamaged

livers were cultured as organoids and analysed at the indicated time points (n3 experiments). Upper panels: hMeDIP (dots, green) and MeDIP (squares, red) levels in the indicated genomic region upstream and downstream of the *Lgr5* TSS. Lower panels: TET1 (blue), TCF4 (brown) and H3K4me3 (purple) ChIP-qPCR at the TSS. mRNA expression is shown in black. *p*-value was obtained using Student's two-tailed t-test. Statistical analyses were performed *vs* t=0h. (Upstream 5hmC 12h p=0.004305136, 18h, p=3.26345E^{-05}, 48h p=8.36527E^{-06}; 5mC 12h p=0.009532377, 18h*,* p=0.001130234, 48h p=0.001564496; TSS 5hmC 12h p=0.011044339, 18h, p=0.005230947, 48h p=0.000485153; Downstream 5hmC 18h p=*0.004305136*, 48h p=3.26345E^{-05}; 5mC 48h p=8.36527E^{-06}; *Lgr5* mRNA 48h p=0.001991489; TET1 ChIP 12h p=0.005403182, 18h, p=0.003789515, 48h p=0.000119801; H3K4me3 ChIP 48h p= 0.000774002). *, p<0.05; **, p <0.01***; p <0.001. **d,** Overlap between the n=1108 DE genes identified in Fig. 2h-i and TET1 targets identified by DamID-seq. *p*-value of the overlap is calculated using normal approximation of the hypergeometric probability. The heatmap (TPM, z-scored) presents the expression profile of the 216 TET1 targets DE *in vivo* and *in vitro*. Graphs show the gene expression levels of n=216 genes (median±95% CI) as ln(TPM +1). *p*-values are obtained with one-way ANOVA followed by Tukey's multiple comparisons test. 0h *vs* 48h p=0.0379, 0h *vs* Org p=0.0039; Und *vs* d3 p=0.0013, Und *vs* d5 p<0.0001.*, p< 0.05; **, p <0.01; ***, p <0.001.

Fig. 6: Tet1 regulates YAP/Hippo and ErbB, MAPK signalling pathways
a, KEGG pathway enrichment and statistical analyses on the genes identified as TET1-DamID targets in liver organoids (n=3) and showing differential levels of 5hmC *in vivo* from RRHP using DAVID 6.8. **b**, TET1 ChIP-qPCRs in liver organoids. Data are reported as percentage of input. Graph represents mean ±SD of n=3 independent experiments. **c**, mRNA expression levels of selected TET1 targets in WT or *RosaCreERT2 x Tet1$^{flx/flx}$* organoids both treated with 5μM tamoxifen for 24hrs. Cells were harvested 24hrs after tamoxifen treatment. Data are reported as fold change compared to Ctrl. Graph represents mean±SD of n=3 independent experiments. *p*-value obtained using Student's two tailed t-test upon comparison to Ctrl. *Egfr*, p= 0.000479886; *Foxo3*, p= 0.031392276; *Jun*, p= 0.004319905; *Gadd45b*, p= 0.023554286; *Ctgf,* p= 0.005333732; *Wwtr1*, p= 0.000230442; *Tead1*, p= 0.002322422. *, p<0.05; **, p<0.01; ***, p<0.001. **d**, mRNA expression levels of YAP/Hippo TET1 targets in Tet1$^{hypo/hypo}$ organoids and TET1$^{hypo-OE}$ organoids. Graph represents mean±SD of n=3 independent experiments. *p*-value obtained using Student's two tailed t-test upon comparison to WT. *Gadd45b*, Tet1$^{hypo/hypo}$ p= 6.00424E^{-05}; TET1$^{hypo-OE}$ p= 6.24089E^{-05}. *Ctgf,* Tet1$^{hypo/hypo}$ p= 0.000677729; TET1$^{hypo-OE}$ p= 0.001247481. *Wwtr1,* Tet1$^{hypo/hypo}$ p= 0.002222631; TET1$^{hypo-OE}$ p= 0.010861863. *Tead1*, Tet1$^{hypo/hypo}$ p= 0.009343297; TET1$^{hypo-OE}$ p= 0.013645094. *, p<0.05; **, p<0.01; ***, p<0.001 **e**, TET1 ChIP-qPCRs in EpCAM^{+} FACS-sorted cells grown in organoid conditions for 18hrs. Data are reported as percentage of input. Graph represents mean ±SD of n=3 independent experiments. **f**, EpCAM^{+} ductal cells freshly isolated from undamaged livers were treated at 0-18hrs or 18-48hrs with the small molecule inhibitors as indicated. Organoid formation was quantified at day 6. Graph represents organoid formation efficiency and indicates mean ±SD of n=6 independent experiments. Statistical analyses were performed with two-ways ANOVA with Bonferroni's multiple compared test *vs* DMSO control group. 18-48hrs Gefitinib, p<0.0001; PD0325901 p<0.0001; Verteporfin, p=0.0039. **, p<0.01; ***, p<0.001. Representative pictures of organoids are shown.

Fig. 7: Tet1 hypomorphic mice exhibit reduced ductal regeneration and extensive fibrosis upon damage

a-b, *WT* (grey) and *Tet1*^{hypo/hypo} mice (blue) were fed normal chow or a chow supplemented with 0.1% DDC for 5 days. **a**, Representative images of immunofluorescence staining for the ductal marker OPN (red) and the proliferation marker Ki67 (white). Scale bar, 25µm. PV, portal vein. Graphs represent the percentage of proliferating (Ki67$^+$) ductal cells (OPN$^+$) (median±IQR) obtained from 55 FOV for *WT* (n=3) and 56 FOV for *Tet1*$^{hypo/hypo}$ mice (n=3) at day 0 (undamaged), and 253 FOV for *WT* (n=7) and 169 FOV for *Tet1*$^{hypo/hypo}$ (n=6) at day5 of DDC damage. Data are represented a boxplots showing the median, IQR and overall range. Grey dots, outliers from a single counted FOV defined as >1.5 IQR above or below the median. Red squares, median level corresponding to each independent mouse. *p*-values were obtained using two-sided Kolmogorov-Smirnov test. ***, p< 2.2x10^{-16}. **b,** Histogram showing the population distribution of proliferating ductal cells (OPN$^+$, Ki67$^+$) by plotting frequency density of counts across the sample range (bar) and the kernel density estimate line. Dashed lines show median values. **c-d,** *WT* (grey) and *Tet1*$^{hypo/hypo}$ (blue) mice were fed normal chow or a chow supplemented with 0.1% DDC for 5 days for 8 consecutive cycles as described in the scheme and methods. Liver tissues were collected 3 months after the last cycle and PicroSirius red staining was performed to analyse the levels of fibrosis (collagen deposition). **c**, Representative images of PicroSirius red staining (red) (3 mice per time point). Scale bar, 200µm. **d,** Graph represents mean±95% CI of the area of collagen deposition per FOV (n=3 mice per time point per genotype). Statistical analysis was performed on the 3 mean values per genotype compared to undamaged using Student's two-tailed t-test. *, p<0.05.

Fig. 8: Ductal specific TET1 depletion results in impaired hepatocyte regeneration

a, Experimental Scheme. **b,** Representative images of 10µm liver sections showing ZsGreen$^+$ ductal cells (OPN$^+$) (n=9 per genotype). Scale bar, 50µm **c,** Graph showing median±IQR of average OPN$^+$ cells per FOV for each individual mouse (n=9 per genotype). Global median level is highlighted in red. *p*-value was calculated using Wilcoxon rank sum test. *, p= 0.03768. **d,** Representative images of 50µm frozen liver sections showing regenerative clusters of ZsGreen$^+$ hepatocytes (HNF4a$^+$) and ductal cells (OPN$^+$). Scale bar, 50µm. **e,** Cumulative relative frequency plots (top graph) and corresponding box plots (bottom graph) showing median (red), upper and lower quartiles and the range (dots represent outliers) of ZsGreen$^+$ hepatocyte cluster size of *Prom1*$^{TET1WT/ZsGreen}$ (n=3) and *Prom1*$^{\Delta Tet1/ZsGreen}$ (n=6) mice. *p*-value was determined by two sided Kolomogorov-Smirnov test. ***, p< 2.2x10^{-16}. **f,** Experimental model.

Extended Data Figure 1: Non-proliferative EpCAM$^+$ ductal cells initiate organoid cultures

a, EpCAM$^+$ ductal cells were isolated from WT livers by FACS using a sequential gating strategy as follows: cells were gated for FSC and SSC and subsequently singlets were gated using FSC/Pulse width. Then, cells were negatively selected for PE/Cy7 (to exclude CD11b$^+$, CD31$^+$ and CD45$^+$ cells) and positively selected for APC (EpCAM$^+$) to obtain CD11b$^-$/CD31$^-$/CD45$^-$/EpCAM$^+$ ductal cells (EpCAM$^+$ cells). These cells give rise to proliferative organoids with ~15% efficiency. Representative bright field pictures of 500 EpCAM$^+$ and EpCAM$^-$ cells 6 days after

seeding. Graph represents mean ±SD of n=3 independent experiments. **b,** RT-qPCR analysis of gene expression of the proliferation marker *mKi67* (left) and stem-cell (*Lgr5*) and ductal (*Epcam* and *Sox9*) markers (right) at the indicated time points after seeding. Graphs represent the mean of n=3 independent experiments. *p*-value obtained using Student's two tailed t-test upon comparison to t= 0h. *, p<0.05; ***, p<0.001. **c,** Proliferation analysis. EdU (10μM) was incorporated to sorted EpCAM⁺ ductal cells at different intervals after seeding (0h, 24h and 48h, arrows) and evaluated by immunofluorescence analysis 24h after each incorporation. Representative images are shown. Scale bar, 10μm. Graph represents the percentage of EdU+ cells. Results are expressed as mean±SD cells from n=3 independent experiments. Student's two tailed t-test statistical analyses were performed *vs* t=24h. *, p<0.05; **, p<0.01; ***, p<0.001

Extended Data Figure 2: Transcriptional changes in ductal cells *in vitro* during liver organoid formation and *in vivo* upon damage
a-e, RNA-seq analysis of ductal cells isolated from adult livers (0h) and at different time points after culture. For DE genes, a pairwise approach with Wald test was performed on each gene using Sleuth. FDR <0.1 was selected as threshold. **a,** Graphs represent the number of significantly DE genes for each comparison. **b,** Hierarchical clustering analysis of epigenetic regulators found DE (383 out of 698 published in ref 49), in at least one comparison. Heatmap represents averaged TPM values scaled per gene. Results are presented as the averaged gene expression of the biological replicates. n, number of replicates. **c-e,** RNA-seq analysis of ductal cells isolated from adult livers (0h) and at day 3 and day 5 after liver damage (2 mice were assessed per time point). The heatmap shows the 1552 DE genes at least in one comparison (TPM>5, FDR<0.1, |b|>0.58). Clustering analysis identified 5 different clusters (Clusters 1-5) according to the expression profile (Cluster 1 n=835; Cluster 2 n=185; Cluster 3 n=503; Cluster 4 n=20; Cluster 5 n=9). Number of genes in each cluster is indicated in brackets. Results are presented as average of the at least 3 biological replicates. **d,** Graph represents the number of significant DE genes in the different comparisons. **e,** GO and statistical analyses of the 3 main clusters identified in **c** were performed using DAVID 6.8.

Extended Data Figure 3: TET1 catalytic activity is required for liver organoid formation and maintenance
a, *Tet1* and *Lgr5* mRNA levels (n=3 mice). Student's two-tailed t-test statistical analyses were performed *vs* undamaged. **b**, *Tet1* mRNA levels (24h after transfection) and organoid formation efficiency 10 days after Tet1 siRNA knock-down using 4 independent Tet1 siRNAs. Data is presented as percentage relative to siCtrl. Graph indicates mean±SD of n=3 independent experiments. Student's two-tailed t-test statistical analyses were performed *vs* siCtrl. **c,** Scheme of the two different *Tet1* alleles used. **d,** *Tet1* mRNA levels in *WT*, *Tet1^hypo/+* and *Tet1^hypo/hypo* and *Tet1* conditional knock-out (cKO) organoids presented as mean±SD of n=3 experiments. **e,** Representative Western blot image showing TET1 protein levels in *WT*, *Tet1^hypo/+* and *Tet1^hypo/hypo* organoids (3 independent experiments). **f**, Organoid formation efficiency from FACS-sorted EpCAM⁺ cells derived from *RosaCre^ERT2* x *Tet1^flx/flx* livers treated with 5μM hydroxytamoxifen (mean±SD of n=3 independent experiments). Student's two-tailed t-test statistical analyses were performed *vs* non-induced control. **g,** Whole mount immunofluorescence staining of 5hmC (green) on *WT*, *Tet1^hypo/hypo,* *hypo-OE* and *hypo-OE^cat.mut.* organoids. Representative images are shown (2 experiments).

732 Scale bar, 50 μm. **h**, Graph represents organoid size at the indicated passages
733 (mean±SD of n=3 independent experiments). Student's two tailed t-test statistical
734 analyses were performed *vs* WT. **i**, Growth curves. **j,** Organoid formation efficiency
735 at the indicated passage expressed as a percentage of organoids. Graphs represent
736 mean±SD of n=3 independent experiments. Student's two tailed t-test statistical
737 analyses were performed *vs* WT. **k**, Representative confocal images of Cleaved
738 Caspase 3 whole mount immunostaining on *WT*, *Tet1$^{hypo/hypo}$*, *hypo-OE* and *hypo-*
739 *OE$^{cat.mut.}$* organoids (2 independent experiments). Scale bar, 25μm.
740
741 **Extended Data Figure 4: WGBS of ductal cells upon damage uncovers a global**
742 **epigenetic remodelling of the DNA methylome**
743 **a**, Number of WGBS unique mapped reads in the different biological replicates. **b**,
744 Bisulfite conversion rate. **c-h**, WGBS analyses were performed in merged biological
745 replicates per time point (n=2). Only CpG sites with ≥3 reads were further analysed.
746 **c**, CpG counts in merged biological replicates per time point. **d**, Genome-wide
747 Spearman's correlation score at the time points analysed shows dynamic CpG
748 modifications. **e**, Functional localisation of DMRs. DMRs were called if the
749 difference in cytosine modification between samples was ≥25% with a p-value of
750 <0.05, using DSS software. **f**, Violin plot of the DMR length distribution (in base
751 pairs) identified in the n=2 biological replicates. Lines and numbers, median. **g**,
752 Density plot indicating the difference in mCpG levels for loss/gain DMRs for each
753 comparison. **h**, Venn diagram showing the overlap between TET1 targets (see Figure
754 5) that are transcriptionally up-regulated and genes showing either loss (left) or gain
755 (right) of mCpG at the TSS according to the WGBS analyses. Hierarchical clustering
756 analyses of the overlapping genes are presented as heatmaps of TPMs scaled per gene
757 (Z-score).
758
759 **Extended Data Figure 5: 5hmC levels increase in ductal cells *in vitro* and *in vivo***
760 **upon damage**
761 **a-c,** EpCAM^{+} ductal cells sorted from 0.1% DDC livers (**a**), β1 integrin mutant mice
762 fed with normal chow (undamaged) or DDC **(b)** or WT undamaged livers and grown
763 as organoids **(c).** 5hmC fluorescence intensity was normalised to DAPI. Data are
764 presented as violin plots of the ratio 5hmC/DAPI. Each dot represents the median
765 value (shown in red) of cells counted/mouse. **a**, 353 cells from n=4 undamaged mice,
766 231 cells from n=5 mice after 3 days of DDC, and 392 cells from n=5 mice at DDC
767 d5; **b,** 138 cells from undamaged, 119 cells at day 1, 247 at day 7 and 125 at day 14
768 after returning the mice to normal chow (recovery) pooled from 2 livers isolated
769 independently from 2 mice were analysed; **c**, 2500 (0h), 900 (24h) and 2000 (48h)
770 cells from n=3 independent experiments were analysed. *p*-values were calculated
771 using pairwise comparisons with Wilcoxon rank sum test. **a**, d3 *vs* d0 p= 1x10^{-13}; d5
772 *vs* d0 p< 2.2x10^{-16}. **c**, 0h *vs* 24h p< 2.2x10^{-16}; 48h *vs* 0h p< 2.2x10^{-16}. Scale bar,
773 10μm. **d**, All 5hmC sites identified by RRHP. **e**, Number of genes associated to TSS
774 showing differential 5hmC levels. The number of CpG sites (n) with unique gain of
775 hydroxymethylation is shown. **f**, Graphs represent distribution of percentage of mCpG
776 identified by WGBS in CGI outside TSS (n=32673) using the average of the 2
777 independent samples (violin plots, black lines median, left) and number of 5hmC
778 counts (median±IQR) in CGI outside TSS (n= 25579) (right). **g,** GO and statistical
779 analyses of the clusters identified in Fig. 4j (Cluster 2 n=347; Cluster 3 n=1659;
780 Cluster 4 n=1424; Cluster 6 n=140) were performed using DAVID 6.8. Heatmap

781 shows the expression profile of the 84 overlapping genes and is presented as averaged
782 Z score of the 2 biological replicates.
783

784 **Extended Data Figure 6: TET1 regulates actively transcribed genes in liver**
785 **organoids**
786 **a-d,** DamID-sequencing was performed in EpCAM[+] sorted ductal cells derived from
787 already established liver organoids (3 independent experiments). Only TET1-Dam
788 peaks identified in all 3 experiments were considered for further analyses. **a**, Scheme
789 of DamID-seq protocol. **b**, Heatmaps showing TET1 peaks identified by DamID-seq
790 (left panels) and H3K4me3 peaks identified by ChIP-seq (right panels). Heatmaps are
791 centred in the middle of the peak (0) and show a genomic window of ±10kb. Top
792 heatmaps represent common peaks between TET1 and H3K4me3 (2848 peaks) while
793 bottom heatmaps represent TET1-specific peaks (2254 peaks). **c**, Pie-chart indicates
794 the percentage of genomic distribution of TET1-Dam peaks. **d**, GO and statistical
795 analyses of biological processes among TET1-Dam targets in liver organoids were
796 performed using DAVID 6.8. n, number of genes. **e,** 5hmC and 5mC levels
797 determined by MeDIP and hMeDIP followed by qPCR on the indicated genomic
798 region surrounding *Lgr5* TSS in *WT* (black), *Tet1*$^{hypo/hypo}$ (blue) and *hypo-OE* (red)
799 organoids. Graphs represent mean of n=3 independent experiments. Student's two
800 tailed was performed comparing samples to WT. *, p<0.05; ** =p <0.01 **f,** TET1
801 ChIP-qPCR at *Lgr5* TSS (left panel) and *Lgr5* mRNA levels (right panel) in *WT*,
802 *Tet1*$^{hypo/hypo}$ and *hypo-OE* organoids. Graphs represent mean±SD of n=3 independent
803 experiments. Student's two tailed t-test statistical analyses were performed *vs* WT. **,
804 p <0.01 **g**, Sorted EpCAM[+] cells from WT livers were cultured in organoid medium
805 and harvested for DNA, chromatin and mRNA expression analyses at the indicated
806 time points. Graphs represent mean of n=3 independent experiments. Student's two
807 tailed t-test analyses were performed *vs* t=0h *, p<0.05; ** =p <0.01; *** =p <0.001
808

809 **Extended Data Figure 7: Treatment with Rapamycin impairs organoid**
810 **formation**
811 **a,** EpCAM[+] ductal cells freshly isolated from the undamaged liver were treated at 0-
812 18hrs or 18-48hrs with the indicated small molecule inhibitors. Organoid formation
813 was quantified at day 6. Graph represents organoid formation efficiency and indicates
814 mean ±SD of n=3 independent experiments. Statistical analyses were performed with
815 two-ways ANOVA with Bonferroni's multiple compared test (*vs* DMSO control
816 group). DMSO control quantifications are shown in Fig. 6f. Representative pictures of
817 organoids treated with the inhibitors at 18-48hrs are shown.
818

819 **Extended Data Figure 8: TET1 hypomorphic mice present a significantly**
820 **impaired ductal regeneration upon damage.**
821 **a,** Graph represents mean ±SD of mouse weight of *WT* (n=21 mice)*, Tet1*$^{hypo/+}$ (n=13
822 mice) and *Tet1*$^{hypo/hypo}$ (n=27 mice) littermates. Student's two tailed t-test statistical
823 analyses were performed. **b**, Relative mouse weight of *WT* (n=5), *Tet1*$^{hypo/+}$ (n=1) and
824 *Tet1*$^{hypo/hypo}$ (n=5) mice. **c**, Representative H&E stainings (3 experiments) of
825 intestines from 50 week old *WT* and *Tet1*$^{hypo/hypo}$ mice. Scale bar, 100μm. **d**,
826 Representative H&E stainings (3 experiments) of small intestine from 10 week old
827 *WT* and *Tet1*$^{hypo/hypo}$ mice treated with DDC for 5 days. Scale bar, 100μm. **e-f**, Box-
828 and-whisker plots showing median and IQR of proliferating ductal cells
829 (OPN[+]/Ki67[+]) during recovery (n=3 *WT* and n=4 *Tet1*$^{hypo/hypo}$ mice) (**e**) or total ductal
830 cells (OPN[+]) at the different time points indicated (**f**) (Undamaged, n=3 *WT* and n=3

831     $Tet1^{hypo/hypo}$ mice ; DDC, n=7 *WT* and n=6 $Tet1^{hypo/hypo}$ mice; Recovery, n=3 *WT* and
832   n=4 $Tet1^{hypo/hypo}$ mice). Grey dots, outliers from a single counted FOV defined as >1.5
833   IQR above or below the median. Red squares, median level corresponding to each
834   independent mice. *p*-values obtained by two-sided Kolmogorov-Smirnov test. **g,**
835   Population distribution of the total number of ductal cells (OPN$^+$) Dashed lines show
836   median values obtained from 55 FOV for *WT* (3 mice) and 56 FOV for $Tet1^{hypo/hypo}$
837   (3mice) at day 0 (undamaged) and 110 FOV for *WT* (3 mice) and 153 FOV for
838     $Tet1^{hypo/hypo}$ (4 mice) at day 12 (recovery). **h,** PCK immunohistochemistry (3
839   experiments) from *WT* (left) and $Tet1^{hypo/hypo}$ (right) undamaged or in recovery after
840   DDC (day 12) livers. Nucleus, Haematoxylin. Scale bar, 100μm. **i,** *Lgr5* and *Tet1*
841   mRNA levels, TET1 ChIP and hMedIP on *Lgr5* TSS were analysed in undamaged
842   and DDC treated livers. Graphs represent mean±SD of values obtained from n=3
843   independent biological replicates (dot). *p*-value was calculated using Student's two-
844   tailed t-test.
845
846   **Extended Data Figure 9: Ductal specific Tet1 conditional deletion impairs duct-**
847   **mediated liver regeneration**
848   **a,** Schematic of the $Prom1Cre^{ERT2}/Rosa^{lslZsGreen}/Tet1^{flx/flx}$ mouse model. **b,**
849   Representative immunofluorescence analysis (OPN$^+$ red, ZsGreen$^+$, green) of
850     $Prom1^{\Delta Tet1/ZsGreen}$ and $Prom1^{Tet1WT/ZsGreen}$ upon tamoxifen treatment and injection of
851   AAV8-TBG p21 (2 mice per genotype). Nucleus, Hoechst. Scale bar, 50 μm **c,**
852   Representative immunofluorescence analysis of livers from $Prom1^{Tet1WT/ZsGreen}$ mice
853   injected with AAV8-TBG p21 not receiving tamoxifen treatment (2 mice per
854   genotype). Scale bar, 100 μm. **d,** *Tet1* expression in EpCAM$^+$/ZsGreen$^+$ ductal cells
855   isolated by FACS from $Prom1^{\Delta Tet1/ZsGreen}$ (n=4) or $Prom1^{Tet/ZsGreen}$ (n=4) livers derived
856   from mice treated for 3-cycles of DDC and collected 12 days after damage. Graph
857   represents mean±SD of *Tet1* expression expressed as a fold change compared to
858     $Prom1^{Tet1WT}$. Student's two tailed t-test statistical analyses were performed. ***,
859   p<0.001. **e,** Representative pictures of P21 immunohistochemistry analyses. Scale bar,
860   200 μm. **f,** Weight curves of mice undergoing AAV8-TBG-p21 injection followed by
861   DDC treatment (mean± 95%CI). **g,** TET1 ChIP-qPCR analyses on target genes in
862   ZsGreen$^+$/EpCAM$^+$ ductal cells isolated from $Prom1^{Tet1WT/ZsGreen}$ DDC-treated livers
863   for 5 days. Cells isolated from 3 mice littermates were pooled used for each
864   independent experiment (n=2). ND, not detected. **h,** Graph represents mean ±SD of
865   mRNA expression of *Tet1* and selected target genes (fold change *vs* WT undamaged)
866   in EpCAM$^+$ ductal cells isolated from undamaged (n=2 per genotype) or day 5 DDC-
867   treated livers (n=3 per genotype) derived from $Prom1^{TET1WT/ZsGreen}$ (grey) or
868     $Prom1^{\Delta Tet1/ZsGreen}$ (blue) mice. Statistical analysis was performed using Student's two-
869   tailed t-test compared to the $Prom1^{TET1WT/ZsGreen}$ value at the corresponding time point.
870
871
872
873

References:

874

875 1 Choi, T. Y., Ninov, N., Stainier, D. Y. & Shin, D. Extensive conversion of
876 hepatic biliary epithelial cells to hepatocytes after near total loss of
877 hepatocytes in zebrafish. *Gastroenterology* **146**, 776-788,
878 doi:10.1053/j.gastro.2013.10.019 (2014).
879 2 Russell, J. O. *et al.* Hepatocyte-specific beta-catenin deletion during severe
880 liver injury provokes cholangiocytes to differentiate into hepatocytes.
881 *Hepatology*, doi:10.1002/hep.30270 (2018).
882 3 Espanol-Suner, R. *et al.* Liver progenitor cells yield functional hepatocytes
883 in response to chronic liver injury in mice. *Gastroenterology* **143**, 1564-
884 1575 e1567, doi:10.1053/j.gastro.2012.08.024 (2012).
885 4 Huch, M. *et al.* In vitro expansion of single Lgr5+ liver stem cells induced
886 by Wnt-driven regeneration. *Nature* **494**, 247-250,
887 doi:10.1038/nature11826 (2013).
888 5 Lu, W. Y. *et al.* Hepatic progenitor cells of biliary origin with liver
889 repopulation capacity. *Nat Cell Biol* **17**, 971-983, doi:10.1038/ncb3203
890 (2015).
891 6 Sackett, S. D. *et al.* Foxl1 is a marker of bipotential hepatic progenitor cells
892 in mice. *Hepatology* **49**, 920-929, doi:10.1002/hep.22705 (2009).
893 7 Shin, S. *et al.* Foxl1-Cre-marked adult hepatic progenitors have clonogenic
894 and bilineage differentiation potential. *Genes Dev* **25**, 1185-1192,
895 doi:10.1101/gad.2027811 (2011).
896 8 Deng, X. *et al.* Chronic Liver Injury Induces Conversion of Biliary Epithelial
897 Cells into Hepatocytes. *Cell stem cell* **23**, 114-122 e113,
898 doi:10.1016/j.stem.2018.05.022 (2018).
899 9 Raven, A. *et al.* Cholangiocytes act as facultative liver stem cells during
900 impaired hepatocyte regeneration. *Nature* **547**, 350-354,
901 doi:10.1038/nature23015 (2017).
902 10 Barker, N. *et al.* Identification of stem cells in small intestine and colon by
903 marker gene Lgr5. *Nature* **449**, 1003-1007, doi:10.1038/nature06196
904 (2007).
905 11 Prior, N. *et al.* Lgr5(+) stem and progenitor cells reside at the apex of a
906 heterogeneous embryonic hepatoblast pool. *Development* **146**,
907 doi:10.1242/dev.174557 (2019).
908 12 Okabe, M. *et al.* Potential hepatic stem cells reside in EpCAM+ cells of
909 normal and injured mouse liver. *Development* **136**, 1951-1960,
910 doi:10.1242/dev.031369 (2009).
911 13 Huch, M. *et al.* Long-term culture of genome-stable bipotent stem cells
912 from adult human liver. *Cell* **160**, 299-312, doi:10.1016/j.cell.2014.11.050
913 (2015).
914 14 Li, B. *et al.* Adult Mouse Liver Contains Two Distinct Populations of
915 Cholangiocytes. *Stem Cell Reports*, doi:10.1016/j.stemcr.2017.06.003
916 (2017).
917 15 Messerschmidt, D. M., Knowles, B. B. & Solter, D. DNA methylation
918 dynamics during epigenetic reprogramming in the germline and
919 preimplantation embryos. *Genes Dev* **28**, 812-828,
920 doi:10.1101/gad.234294.113 (2014).

921 16 Iurlaro, M., von Meyenn, F. & Reik, W. DNA methylation homeostasis in
922   human and mouse development. *Curr Opin Genet Dev* **43**, 101-109,
923   doi:10.1016/j.gde.2017.02.003 (2017).
924 17 Smith, Z. D. & Meissner, A. DNA methylation: roles in mammalian
925   development. *Nat Rev Genet* **14**, 204-220, doi:10.1038/nrg3354 (2013).
926 18 Bird, A. DNA methylation patterns and epigenetic memory. *Genes Dev* **16**,
927   6-21, doi:10.1101/gad.947102 (2002).
928 19 Li, E. & Zhang, Y. DNA methylation in mammals. *Cold Spring Harb Perspect*
929   *Biol* **6**, a019133, doi:10.1101/cshperspect.a019133 (2014).
930 20 Probst, A. V., Dunleavy, E. & Almouzni, G. Epigenetic inheritance during
931   the cell cycle. *Nat Rev Mol Cell Biol* **10**, 192-206, doi:10.1038/nrm2640
932   (2009).
933 21 Kohli, R. M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA
934   demethylation. *Nature* **502**, 472-479, doi:10.1038/nature12750 (2013).
935 22 Pastor, W. A., Aravind, L. & Rao, A. TETonic shift: biological roles of TET
936   proteins in DNA demethylation and transcription. *Nat Rev Mol Cell Biol*
937   **14**, 341-356, doi:10.1038/nrm3589 (2013).
938 23 Hill, P. W., Amouroux, R. & Hajkova, P. DNA demethylation, Tet proteins
939   and 5-hydroxymethylcytosine in epigenetic reprogramming: an emerging
940   complex story. *Genomics* **104**, 324-333, doi:10.1016/j.ygeno.2014.08.012
941   (2014).
942 24 Hahn, M. A., Szabo, P. E. & Pfeifer, G. P. 5-Hydroxymethylcytosine: a stable
943   or transient DNA modification? *Genomics* **104**, 314-323,
944   doi:10.1016/j.ygeno.2014.08.015 (2014).
945 25 Branco, M. R., Ficz, G. & Reik, W. Uncovering the role of 5-
946   hydroxymethylcytosine in the epigenome. *Nat Rev Genet* **13**, 7-13,
947   doi:10.1038/nrg3080 (2011).
948 26 Yamaguchi, S., Shen, L., Liu, Y., Sendler, D. & Zhang, Y. Role of Tet1 in
949   erasure of genomic imprinting. *Nature* **504**, 460-464,
950   doi:10.1038/nature12805 (2013).
951 27 Hill, P. W. S. *et al.* Epigenetic reprogramming enables the transition from
952   primordial germ cell to gonocyte. *Nature* **555**, 392-396,
953   doi:10.1038/nature25964 (2018).
954 28 Ficz, G. *et al.* Dynamic regulation of 5-hydroxymethylcytosine in mouse ES
955   cells and during differentiation. *Nature* **473**, 398-402,
956   doi:10.1038/nature10008 (2011).
957 29 Costa, Y. *et al.* NANOG-dependent function of TET1 and TET2 in
958   establishment of pluripotency. *Nature* **495**, 370-374,
959   doi:10.1038/nature11925 (2013).
960 30 Rasmussen, K. D. & Helin, K. Role of TET enzymes in DNA methylation,
961   development, and cancer. *Genes Dev* **30**, 733-750,
962   doi:10.1101/gad.276568.115 (2016).
963 31 Kim, R., Sheaffer, K. L., Choi, I., Won, K. J. & Kaestner, K. H. Epigenetic
964   regulation of intestinal stem cells by Tet1-mediated DNA
965   hydroxymethylation. *Genes Dev* **30**, 2433-2442,
966   doi:10.1101/gad.288035.116 (2016).
967 32 Reizel, Y. *et al.* Postnatal DNA demethylation and its role in tissue
968   maturation. *Nature communications* **9**, 2040, doi:10.1038/s41467-018-
969   04456-6 (2018).

970 33 Tarlow, B. D., Finegold, M. J. & Grompe, M. Clonal tracing of Sox9+ liver
971 progenitors in mouse oval cell injury. *Hepatology* **60**, 278-289,
972 doi:10.1002/hep.27084 (2014).
973 34 Dorrell, C. *et al.* Prospective isolation of a bipotential clonogenic liver
974 progenitor cell in adult mice. *Genes Dev* **25**, 1193-1203,
975 doi:10.1101/gad.2029411 (2011).
976 35 Mort, R. L. *et al.* Fucci2a: a bicistronic cell cycle reporter that allows Cre
977 mediated tissue specific expression in mice. *Cell Cycle* **13**, 2681-2696,
978 doi:10.4161/15384101.2015.945381 (2014).
979 36 Duncan, A. W., Dorrell, C. & Grompe, M. Stem cells and liver regeneration.
980 *Gastroenterology* **137**, 466-481, doi:10.1053/j.gastro.2009.05.044 (2009).
981 37 Medvedeva, Y. A. *et al.* EpiFactors: a comprehensive database of human
982 epigenetic factors and complexes. *Database (Oxford)* **2015**, bav067,
983 doi:10.1093/database/bav067 (2015).
984 38 Huch, M. & Koo, B. K. Modeling mouse and human development using
985 organoid cultures. *Development* **142**, 3113-3125,
986 doi:10.1242/dev.118570 (2015).
987 39 Tahiliani, M. *et al.* Conversion of 5-methylcytosine to 5-
988 hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science*
989 **324**, 930-935, doi:10.1126/science.1170116 (2009).
990 40 Natarajan, A., Wagner, B. & Sibilia, M. The EGF receptor is required for
991 efficient liver regeneration. *Proceedings of the National Academy of*
992 *Sciences of the United States of America* **104**, 17081-17086,
993 doi:10.1073/pnas.0704126104 (2007).
994 41 Yang, L. *et al.* A single-cell transcriptomic analysis reveals precise
995 pathways and regulatory mechanisms underlying hepatoblast
996 differentiation. *Hepatology* **66**, 1387-1401, doi:10.1002/hep.29353
997 (2017).
998 42 Marshall, O. J., Southall, T. D., Cheetham, S. W. & Brand, A. H. Cell-type-
999 specific profiling of protein-DNA interactions without cell isolation using
1000 targeted DamID with next-generation sequencing. *Nat Protoc* **11**, 1586-
1001 1598, doi:10.1038/nprot.2016.084 (2016).
1002 43 Cheetham, S. W. *et al.* Targeted DamID reveals differential binding of
1003 mammalian pluripotency factors. *Development* **145**,
1004 doi:10.1242/dev.170209 (2018).
1005 44 Hu, M. *et al.* Wnt/beta-catenin signaling in murine hepatic transit
1006 amplifying progenitor cells. *Gastroenterology* **133**, 1579-1591,
1007 doi:10.1053/j.gastro.2007.08.036 (2007).
1008 45 Wang, B., Zhao, L., Fish, M., Logan, C. Y. & Nusse, R. Self-renewing diploid
1009 Axin2(+) cells fuel homeostatic renewal of the liver. *Nature* **524**, 180-185,
1010 doi:10.1038/nature14863 (2015).
1011 46 Jensen, K. B. *et al.* Lrig1 expression defines a distinct multipotent stem cell
1012 population in mammalian epidermis. *Cell stem cell* **4**, 427-439,
1013 doi:10.1016/j.stem.2009.04.014 (2009).
1014 47 Chrysanthou, S. *et al.* A Critical Role of TET1/2 Proteins in Cell-Cycle
1015 Progression of Trophoblast Stem Cells. *Stem Cell Reports* **10**, 1355-1368,
1016 doi:10.1016/j.stemcr.2018.02.014 (2018).

1017   48   Boj, S. F. *et al.* Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls
1018   hepatic response to perinatal and adult metabolic demand. *Cell* **151**,
1019   1595-1607, doi:10.1016/j.cell.2012.10.053 (2012).

1020   49   Fouraschen, S. M. *et al.* mTOR signaling in liver regeneration: Rapamycin
1021   combined with growth factor treatment. *World journal of transplantation*
1022   **3**, 36-47, doi:10.5500/wjt.v3.i3.36 (2013).

1023   50   Planas-Paz, L. *et al.* YAP, but Not RSPO-LGR4/5, Signaling in Biliary
1024   Epithelial Cells Promotes a Ductular Reaction in Response to Liver Injury.
1025   *Cell stem cell* **25**, 39-53 e10, doi:10.1016/j.stem.2019.04.005 (2019).

1026   51   Talarmin, H. *et al.* The mitogen-activated protein kinase
1027   kinase/extracellular signal-regulated kinase cascade activation is a key
1028   signalling pathway involved in the regulation of G(1) phase progression in
1029   proliferating hepatocytes. *Molecular and cellular biology* **19**, 6003-6011,
1030   doi:10.1128/mcb.19.9.6003 (1999).

1031   52   Pepe-Mooney, B. J. *et al.* Single-Cell Analysis of the Liver Epithelium
1032   Reveals Dynamic Heterogeneity and an Essential Role for YAP in
1033   Homeostasis and Regeneration. *Cell stem cell* **25**, 23-38 e28,
1034   doi:10.1016/j.stem.2019.04.004 (2019).

1035   53   Yimlamai, D. *et al.* Hippo pathway activity influences liver cell fate. *Cell*
1036   **157**, 1324-1338, doi:10.1016/j.cell.2014.03.060 (2014).

1037   54   Serra, D. *et al.* Self-organization and symmetry breaking in intestinal
1038   organoid development. *Nature* **569**, 66-72, doi:10.1038/s41586-019-
1039   1146-y (2019).

1040   55   Lin, Y. *et al.* HGF/R-spondin1 rescues liver dysfunction through the
1041   induction of Lgr5(+) liver stem cells. *Nature communications* **8**, 1175,
1042   doi:10.1038/s41467-017-01341-6 (2017).

1043   56   Kamimoto, K. *et al.* Heterogeneity and stochastic growth regulation of
1044   biliary epithelial cells dictate dynamic epithelial tissue remodeling. *eLife*
1045   **5**, doi:10.7554/eLife.15034 (2016).

1046   57   Zhu, L. *et al.* Multi-organ Mapping of Cancer Risk. *Cell* **166**, 1132-1146
1047   e1137, doi:10.1016/j.cell.2016.07.045 (2016).

1048   58   Blanpain, C. & Fuchs, E. Stem cell plasticity. Plasticity of epithelial stem
1049   cells in tissue regeneration. *Science* **344**, 1242281,
1050   doi:10.1126/science.1242281 (2014).

1051   59   Lin, S. *et al.* Distributed hepatocytes expressing telomerase repopulate the
1052   liver in homeostasis and injury. *Nature* **556**, 244-248,
1053   doi:10.1038/s41586-018-0004-7 (2018).

1054   60   Font-Burgada, J. *et al.* Hybrid Periportal Hepatocytes Regenerate the
1055   Injured Liver without Giving Rise to Cancer. *Cell* **162**, 766-779,
1056   doi:10.1016/j.cell.2015.07.026 (2015).

1057   61   Huch, M. & Dolle, L. The plastic cellular states of liver cells: Are EpCAM
1058   and Lgr5 fit for purpose? *Hepatology* **64**, 652-662,
1059   doi:10.1002/hep.28469 (2016).

1060   62   Michalopoulos, G. K. The liver is a peculiar organ when it comes to stem
1061   cells. *Am J Pathol* **184**, 1263-1267, doi:10.1016/j.ajpath.2014.02.020
1062   (2014).

1063   63   Forbes, S. J. & Rosenthal, N. Preparing the ground for tissue regeneration:
1064   from mechanism to therapy. *Nat Med* **20**, 857-869, doi:10.1038/nm.3653
1065   (2014).

1066　64　Hall, C. *et al.* Regulators of Cholangiocyte Proliferation. *Gene Expr* **17**, 155-
1067　　　　171, doi:10.3727/105221616X692568 (2017).
1068　65　Lazaridis, K. N. & LaRusso, N. F. The Cholangiopathies. *Mayo Clin Proc* **90**,
1069　　　　791-800, doi:10.1016/j.mayocp.2015.03.017 (2015).
1070　66　Tanaka, E. M. & Reddien, P. W. The cellular basis for animal regeneration.
1071　　　　*Developmental cell* **21**, 172-185, doi:10.1016/j.devcel.2011.06.016
1072　　　　(2011).
1073　67　Jin, S. G. *et al.* 5-Hydroxymethylcytosine is strongly depleted in human
1074　　　　cancers but its levels do not correlate with IDH1 mutations. *Cancer*
1075　　　　*research* **71**, 7360-7365, doi:10.1158/0008-5472.CAN-11-2023 (2011).
1076　68　Thomson, J. P. *et al.* Loss of Tet1-Associated 5-Hydroxymethylcytosine Is
1077　　　　Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer.
1078　　　　*Cancer research* **76**, 3097-3108, doi:10.1158/0008-5472.CAN-15-1910
1079　　　　(2016).
1080　69　Kafer, G. R. *et al.* 5-Hydroxymethylcytosine Marks Sites of DNA Damage
1081　　　　and Promotes Genome Stability. *Cell reports* **14**, 1283-1292,
1082　　　　doi:10.1016/j.celrep.2016.01.035 (2016).
1083
1084

1085　**Methods:**

1086　**Liver isolation, FACS sorting, culture and transfection**

1087　Undamaged or DDC damaged livers were isolated from 8-12 weeks old mice and

1088　digested using collagenase/dispase (0.125mg/ml in DMEM/F12) as previously

1089　published[4,70]. To obtain a population of ductal cells, cells were stained with CD11b-

1090　PE/Cy7 (BD Biosciences), CD45-PE/Cy7 (BD Biosciences), CD31-PE/Cy7 (Abcam)

1091　and EpCAM-APC antibody (eBioscience) (Supplementary Dataset 5) and FACS-

1092　sorted using a MoFlo cell sorter. The following sorting strategy was pursued: single

1093　cells were sequentially gated based on cell size (forward scatter, FSC, versus side

1094　scatter, SSC) and singlets (pulse width vs FSC) and then ductal cells were selected

1095　based on EpCAM positivity after excluding macrophages (CD11+), blood cells

1096　(CD45+) and endothelial cells (CD31+), hence obtaining a pure population of single

1097　$CD11b^-/CD31^-/CD45^-/EpCAM^+$, named $EpCAM^+$ from here on (see Supplementary

1098　Dataset 5 for antibody list). In order to determine the phase of the cell-cycle,

1099　$EpCAM^+$ cells derived from *R26Fucci2a* mice[35] were further gated for mCherry-

1100　hCtd1(30/120) (G1/G0) and mVenus-hGem(1/110) (S/G2/M).

1101　Sorted cells were seeded in matrigel and cultured in Advanced DMEM/F12 (Gibco)

1102　supplemented with Penicillin/Streptomycin, Glutamax and HEPES (all from Gibco),

1103　and 1xN2 (Gibco), 1xB27 (Gibco), 500nM n-Acetylcysteine (Sigma), 10nM Gastrin

1104　(Sigma), 50ng/ml EGF (Peprotech), 100ng/ml FGF10 (Peprotech), 50ng/ml HGF

1105　(Peprotech), 10mM Nicotinamide (Sigma), 10% R-spondin1 conditioned medium

1106   (home-made), 25ng/ml Noggin (Peprotech), 30% Wnt conditioned medium (home-

1107   made) and 10uM of Rock inhibitor Y-27632 (Sigma), as previously reported[4,70]. After

1108   48h, Wnt conditioned medium, Noggin and Rock inhibitor were removed from the

1109   culture medium.

1110   Organoid formation efficiency from ductal sorted cells was determined by seeding

1111   single cells at 500 cells/well and counting organoid numbers/well 6 days later.

1112   Organoid formation efficiency from organoid cultures was determined by dissociating

1113   organoids into single cells following TrypleE (Gibco) incubation for 10min. Cells

1114   were then seeded at 500 cells/well and number of organoids/well was counted after 6

1115   days.

1116   For experiments with small molecule inhibitors, EpCAM$^+$ ductal cells were grown for

1117   the time and concentration indicated in the legend with Verteporfin (Tocris, 5305),

1118   Gefinitib (Stratech Scientific, S1025), PD0325901 (Sigma, PZ0162), Rapamycin

1119   (Sigma, R8781) and PD173074 (Tocris, 3044).

1120   For EdU studies, a 24h pulse of EdU was performed in FACS-sorted EpCAM$^+$ cells at

1121   0-24h, 24-48h, 48-72h after seeding. Cells were then cytospun, using to Click-iT EdU

1122   Alexa Fluor 594 Imaging Kit (Molecular Probes) according to manufacturer's

1123   instructions.

1124   For treatment of Cre^{ERT2} positive cells *in vitro*, 5mM of (Z)-4-Hydroxytamoxifen

1125   (Sigma) was added o/n to the medium.

1126   To perform siRNA experiments, 1×10^4 EpCAM$^+$ cells freshly isolated from

1127   undamaged livers were transfected either with a pool of 4 ON-Targetplus siRNA

1128   (Dharmacon) for each candidate gene (screen) or with 4 independent *Tet1* siRNA,

1129   using Lipofectamine RNAimax (Life Technologies) according to manufacturer's

1130   instructions. Briefly, cells and Lipofectamine-RNA mix were spun at 600g at 32°C or

1131   45min and then incubated 4h at 37C. Cell suspension was then collected and seeded

1132   in matrigel in Isolation medium. Organoid formation efficiency was assessed 6 days

1133   later. siRNAs used are listed in Supplementary Dataset 5.

1134   To generate stable organoid lines, ectopically expressing full-length hTET1 cDNA

1135   (TET1wt) or catalytically inactive TET1 (H1671Y, D1673A) (TET1 cat.mut.)

1136   reported in[29,39]. Cells were transfected into 5×10^4 CD11b$^-$/CD31$^-$/CD45$^-$/EpCAM$^+$

1137   freshly isolated cells using Lipofectime 2000 (Life Technologies) according to

1138   manufacturer's instructions. Briefly, cells and Lipofectamine-DNA mix were spun at

1139   600g at 32°C for 45min and then incubated 4h at 37C. Cell suspension was then

1140 collected, spun for 5min at 300g and seeded in matrigel in Isolation medium for 48h

1141 and then switched to expansion medium. Blasticidin (2μg/ml) was added 48h after

1142 transfection in expansion medium in order to maintain stable expression of the

1143 transgenes. Organoid formation efficiency was assessed 6 days later.

1144 hTET1 cDNA was cloned into a Mammalian Targeted DamID vector with a CAG-

1145 promoter downstream of LT3-Dam[43] to create a Dam-hTET1 fusion protein using

1146 Gibson assembly. Organoids were transiently transfected as described above with

1147 either a Dam-only or Dam-hTET1 fusion construct, together with pCAG-Venus at a

1148 3:1 ratio. Around 5×10^3, 2.5×10^4 and 4.5×10^4 Venus$^+$ cells were FACS-sorted 72h

1149 later and processed independently for each the 3 biological replicates respectively.

1150

1151 **<u>5hmC/EdU immunocytochemistry</u>**

1152 EdU/5hmC staining was performed in FACS-sorted cells fixed in 4%

1153 paraformaldehyde (PFA) at time (0h) or embedded in matrigel and cultured in

1154 Isolation Medium for 24h and 48h. For the latter two conditions, EdU was added to

1155 the medium at 10μM for a 24h pulse (namely from 0-24h and from 24-48h). Cells

1156 were fixed with 4% PFA within the matrigel bubble and extracted by washing with

1157 cold Advanced DMEM/F12. Cells were cytospun onto SuperFrost Plus slides (VWR)

1158 and stained using the Click-iT EdU Alexa Fluor 594 Imaging Kit (Molecular Probes)

1159 according to manufacturer's instructions. Cells were permeabilised and blocked

1160 simultaneously with PBS containing 1% Triton, 1% DMSO, 1% BSA and 2% donkey

1161 serum for 25min, after which they were treated with 2N HCl at RT for 20min.

1162 Following thorough washes with PBS, the cells were incubated with the 5hmC

1163 primary antibody (Active Motif, 39769, Supplementary Dataset 5) at 1:1000 dilution

1164 in permeabilisation/blocking buffer pre-diluted 1:100 in PBS. After washing with

1165 PBS, cells were incubated for 90min with an anti-rabbit Alexa 488 secondary

1166 antibody at a 1:250 dilution in PBS containing 0.05% BSA. Nuclei were

1167 counterstained with DAPI at 0.5μg/ml in water. Cover slips were mounted with

1168 Vectashield (Vector Laboratories) and sealed with nailpolish. The quantification of

1169 the intensity of 5hmC levels was performed with an in-house designed macro for the

1170 Fiji software [71]; EdU+ cells were counted manually.

1171 Confocal images were captured on a Leica SP5 inverted confocal microscope, (LAS

1172 AF) and processed with Volocity 6.3 (PerkinElmer). The quantification of the

1173   intensity of 5mC levels was performed with an in-house designed macro for the Fiji

1174   software.

1175

1176   **<u>Whole Genome Bisulfite Sequencing (WGBS) library preparation and analysis</u>**

1177   Ductal cells were isolated from 2 independent 8-12 weeks old mice per time point and

1178   split for libraries preparation. High-molecular-weight genomic DNA (HMW gDNA)

1179   was extracted by first lysing the cells in lysis buffer [20mM Tris pH8, 4mM EDTA,

1180   20mM NaCl, 1%SDS] and proteinase K [ThermoFisher, #EO0491] for 90min at

1181   56ºC), then by treating lysate with RNase A (#EN0531, ThermoFisher) for 5min at

1182   RT. gDNA was extracted using Phenol/chloroform (Phenol:Chloroform:Isoamyl

1183   Alcohol 25:24:1, Invitrogen #15593031). HMW gDNA was then sonicated to

1184   fragment size of 300-400bp (Covaris, E220), following manufacturer's instructions.

1185   Fragments were then purified using PureLink PCR Purification kit (ThermoFisher,

1186   #K310001) and purity and length were determined using NanoDrop, Qubit and

1187   Tapestation (Agilent). To estimate bisulfite conversion efficiency, un-methylated

1188   lambda phage cl857 Sam7 DNA was used as spike-in (0.5% of total DNA amount).

1189   Typically, NGS libraries were prepped using 200ng of sonicated fragments using

1190   NEBNext Ultra II DNA Library Prep, following manufacturer's instructions (New

1191   England BioLabs, E7645S). Briefly, blunt fragments are first end-repaired and A-

1192   tailed using T4 DNA polymerase and Klenow Fragment. They are then ligated on

1193   both flanks with Illumina methylated adaptors (NEB, E7535S). Adapted fragments

1194   were then purified with Agencourt AMPure Beads at a 0.8x ratio (Beckman Coulter,

1195   Inc). Libraries (~50ng) were then treated with sodium bisulfite according to the

1196   protocol (Imprint DNA Modification Kit; Sigma, MOD50) and then barcoded

1197   (NEBNext Multiplex Oligos for Illumina, NEB E7335S) and amplified by PCR (8

1198   PCR cycles) with KAPA HiFi HS Uracil+ RM (KAPA Biosystems). Indexed libraries

1199   were sequenced on HiSeq 4000 (High Output mode, v.4 SBS chemistry, at CRUK,

1200   Cambridge Institute, UK) to generate 150bp paired reads.

1201   Quality of sequenced read pairs was determined, and adaptor sequences and low

1202   quality reads removed using TrimGalore `--paired --fastqc --illumina`

1203   (v0.4.4_dev, Babraham Inst.). Adaptor-trimmed paired reads were aligned to the

1204   mouse assembly GRCm38.p6 and to the lambda genome (used to determine bisulfite

1205   non-conversion rate) using Bismark[27] (v0.19.0). Single-end reads from un-aligned

1206   paired-end reads were also mapped. Alignment parameters were: 1 mapping mismatch

1207 allowed with a maximum insert size for valid paired-end read alignments of 500bp (`-`

1208 `N 1 -X 500`, respectively). Clonal reads were removed using `deduplicate_bismark`.

1209 Methylation at CpG sites was called using `bismark_methylation_extractor -`

1210 `no_overlap --ignore_r2 2` and `methylpy call-methylation-state` using

1211 merged paired end and single end reads. Biological duplicates were merged for overall

1212 methylome profiling and only CpG sites with ≥3 unique mapped reads were used for

1213 analyses. DMRs (default parameters with DNA methylation differences of ≥25%

1214 between groups) were generated using R package DSS (v2.26.0) and CGI for

1215 GRCm38.p6 were predicted as previously published[72]. For analysis of cytosine

1216 modifications (5mC and 5hmC) on up-regulated genes *in vivo*, levels of modification

1217 at CpG context (mCpG) were averaged over TSS regions (+/- 500bp) of genes (given

1218 as percentage of mCpG). WGBS analyses, including gene expression correlation and

1219 Spearman correlation, were done using DSS (v2.26.0), methylpy (v1.2.9), R (v3.4.4),

1220 using custom scripts. Samtools (v1.5) and bedtools (v2.26.0) were used to generate

1221 and analyse mapped reads. R packages ggplot2 (v2.3.0) and pheatmap (v1.0.10) were

1222 used to visualise data.

1223

1224 **Reduced Representation of Hydroxymethylation Profile (RRHP) library**

1225 **preparation and analysis**

1226 Genomic DNA from was extracted using phenol/chloroform as described in WGBS

1227 section. Quality and purity of gDNA was assessed using Nanodrop and Tapestation.

1228 500ng of gDNA was then used to produce RRHP data according to manufacter's

1229 instructions (Zymo Research D5450). RRHP libraries were multiplexed and

1230 sequenced on HiSeq 4000 at Gurdon Institute (single end 50bp).

1231 Adaptor sequences in sequenced reads and low-quality reads were removed using

1232 trimGalore (0.4.4_dev, options: `--rrbs --fastqc --illumina`). Trimmed reads

1233 were then mapped to GRCm38.p6 mouse genome using bowtie2 (version 2.3.3.1,

1234 options: `--end-to-end`). Then, only reads with the 5′-CCGG tag were further

1235 analysed. Unique CCGG sites were counted genome-wide and only 5hmC sites

1236 present in both biological replicates were analysed. To identify differential

1237 hydroxymethylation levels, TSS regions (+2,-1 kbp around TSS) showing ≥4 unique

1238 5hmC sites at any time points were analysed. Heatmaps of 5hmC show scaled values

1239 of absolute 5hmC count at TSS present in both biological replicates for each group.

1240 The non-parametric Kruskal-Wallis test by ranks was used to compare 5hmC levels

1241 between groups, followed by Dunn's test to correct for multiple testing (adjusted p-
1242 values of <0.05 were considered significant). Statistical tests were performed using
1243 Prism (v8.0).

1244

1245 **Time-lapse microscopy and Image analysis**

1246 Time-lapse images of single FACS-sorted ductal cells were acquired on an inverted
1247 spinning disk confocal microscope (3i Intelligent Imaging Innovations) with a Zeiss
1248 LD C-Apochromat 40x (1.1 numerical aperture, NA) immersion objective. Cells were
1249 imaged in a humidified chamber with 5% CO_2. Images were taken at intervals of
1250 60min with a Z-step of 2.4μm. Time-lapse acquisition were processed with the
1251 Slidebook6 software and analysed by Fiji image processing software, as previously
1252 described[73].

1253

1254 **RNA-sequencing and analyses**

1255 EpCAM[+] freshly isolated cells were isolated from undamaged or DDC-damaged
1256 livers (day 3 and 5) for RNA extraction or embedded in matrigel and collected at
1257 different time points after culture (time 12h, 24h, 48h and 6 days, the later named as
1258 organoids). The starting time point (0h) was collected after seeding in matrigel but
1259 prior to adding any medium. Total RNA was extracted using PicoPure RNA isolation
1260 kit (ThermoFisher Scientific) according to manufacturer's instructions. RNA libraries
1261 were prepared by using Smartseq2[74]. RNA sequencing was performed using Illumina
1262 Hiseq sequencer at the Gurdon Institute. Quality of sequenced read pairs was
1263 determined, adaptor sequences and low quality reads removed using `TrimGalore --`
1264 `paired --fastqc --illumina` (v0.4.4). Reads were mapped and quantified (TPM)
1265 using kallisto v0.43.1 (`kallisto quant --bias --single -b 100 -l 500 -s 80`
1266 `-t 1`) with the mouse assembly GRCm38.p6. Differential gene expression was
1267 performed using sleuth (v0.29.0; sleuth_lrt: likelihood ratio test) with FDR <0.1, with
1268 sequencing batch effect adjustment. Only DE genes with a maximal TPM of >5 at >1
1269 time point (T0, D3 or D5) and showing considerable expression level difference
1270 (|b|>0.58) were analysed. Principal component analysis (centered and scaled) were
1271 produced with build-in R programme `prcomp`. Mean TPM values between biological
1272 replicates of each group were used for downstream analysis. Graphs and heatmaps
1273 were produced with R packages ggplot2, rgl and pheatmap. Heatmap of gene

expression are scaled TPM values (z score). The list of epigenetic regulators was found in the database Epifactors[37].

Organoid whole mount immunostaining

Organoids removal from matrigel was performed by mechanically disrupting the matrigel by gently pipetting 5 times and then incubated for 10min in cold Advanced DMEM/F12 medium. Cells were fixed with PFA 4% for 30min on ice and incubated with blocking solution (PBS 1%Triton 1%BSA in PBS) for 1.5 hours. For 5hmC staining, organoids were treated for 20min with 2N HCl before incubation with the primary antibody followed by 3 washes in 1% blocking solution. Primary antibodies were incubated o/n at 4°C Fluorophore-conjugated secondary antibodies were then incubated for 2h. Nuclei were stained with DAPI. Confocal images were captured on a Leica SP5 inverted confocal microscope and processed with Leica LasX software.

Quantitative PCR (qPCR)

Total RNA was extracted from freshly isolated EpCAM$^+$ cells or cultured in isolation or expansion medium (organoid cultures) using PicoPure RNA isolation kit (ThermoFisher Scientific) according to manufacturer instructions. cDNA was synthesized using 50-250ng of total RNA and a M-MLV Reverse Transcriptase kit (Promega). cDNA was amplified with iTaq™ Universal SYBR Green Supermix (BioRad) and specific primers (see Supplementary Dataset 5). All targets were amplified (40 cycles) on a CFX96 Real-Time qPCR Detection System (Biorad). Ct values were analyzed using BioRad CFX manager. Expression levels were normalized to the expression of the housekeeping gene *Hprt*.

5mC and 5hmC DNA immunoprecipitation (MeDIP and hMeDIP) and chromatin immunoprecipitation (ChIP)

Genomic DNA was extracted by incubating either sorted EpCAM$^+$ cells (freshly isolated or cultured in matrigel in isolation or expansion medium) or dissociated organoids with lysis buffer (50mM Tris HCl PH8.0, 50mM NaCl, 5mM EDTA, 1.0% SDS) for 10min at 4°C Genomic DNA was sheared by sonication (Bioruptor, Diagenode) to 200-500bp average fragments and purified using MinElute PCR purification micro kit (Qiagen). The following immunoprecipitation buffer was used: 50mM Tris HCl PH8, 250mM NaCl, 5mM EDTA, 0,5% Triton, 0,10% SDS. TET1

1308 (Millipore 09-872 and ABE1034) and H3K4me3 (Diagenode C1541003) primary
1309 antibodies (Supplementary Dataset 5) were incubated o/n and immunocomplexes
1310 were recovered with DiaMag Protein A or G coated magnetic beads (Diagenode).
1311 ChIP-qPCR experiments were then performed on genomic regions of interest and data
1312 were normalised to IgG and expressed as percentage of input material (see
1313 Supplementary Dataset 5 for primer list). Chromatin Immunoprecipitation (ChIP)
1314 experiments from cells freshly isolated from liver tissue were performed using
1315 LowCell ChIP kit (Diagenode) followed by iPure kit v2 (Diagenode) according to
1316 manufacture's instructions. ChIP experiments for cells grown *in vitro* as organoid
1317 were performed as previously described[75]. DNA derived from 2 independent
1318 biological H3K4me3 ChIP experiments in liver organoids was pulled and processed
1319 using Thruplex DNA seq kit according to manufacturer's instructions. The library
1320 was sequenced in-house using an Illumina Hiseq 1500. H3K4me3 ChIP-seq reads were
1321 mapped to GRCM38/mm10 with bowtie2 (v2.2.9). Peak calling on H3K4me3 ChIP-
1322 seq was done using MACS2 (v2.1.0) (broad, q<0.01) on individual bam-files, with
1323 input as a control. Genes were called from peaks using GREAT (v3.0.0)[76] (single
1324 nearest gene, +/-2kb from TSS). Plots were generated through SeqPlots (v1.12.1)[77].
1325

DamID sequencing

1327 Cells obtained by trypsin-mediated dissociation of mouse liver organoids were
1328 transfected with hTET1-Dam or Dam-only vector together with Venus-encoding
1329 plasmid (see above). DamID-seq on Venus[+] FACS-sorted cells was performed as
1330 previously described[42]. All sequencing experiments were performed as single-end
1331 50bp reads generated by the Gurdon Institute NGS Core using an Illumina HiSeq
1332 1500. DamID sequencing data from three paired replicates were mapped to
1333 GRCM38/mm10 and processed using the damidseq_pipeline script[78], with default
1334 settings apart from a 300 bin-width. Peak-calling on DamID samples was done using
1335 MACS2 (v2.1.0) (broad, q<0.01) on individual bam-files, with Dam-only as control.
1336 Peak files from all replicates were merged and intersected with every single replicate
1337 with bedtools (v2.25.0) to obtain those peak-regions, which were only present in all
1338 three replicates with a q-value <0.01. Genes were called from peaks using GREAT
1339 (v3.0.0)[76] (single nearest gene, +/-2kb from TSS). Plots were generated through
1340 SeqPlots (v1.12.1)[77]. Peaks were annotated to overlapping genomic features with the

1341   ChIPseeker-package (v1.18.0) in R using annotations and gene IDs from
1342   TxDb.Mmusculus.UCSC.mm10.knownGene and org.Mm.eg.db (v3.4.4). DamID data
1343   are presented as Dam-hTETt1/Dam ratios with the midline at 1.

1344

1345   **<u>Western blot assay</u>**

1346   Cell lysates were prepared using RIPA buffer (10mM Tris-Hcl PH 8.0m 1mM EDTA,

1347   1% Triton X-100, 0.1% SDS. 150mM NaCl) supplemented with proteinase inhibitor

1348   cocktail (Roche) and sonicated for 5min using a Bioruptor sonicator (Diagenode).

1349   Lysates were cleared by centrifugation at 13,000rpm for 15min. Samples were loaded

1350   on Precast Mini Protean TGX gels (Biorad) and transferred on nitrocellulose

1351   membrane (Biorad), which was blocked in 5% milk and incubated O.N. with TET1

1352   (Millipore 09-872) (1:1000) or actin (Abcam ab3280) (1:2000) (Supplementary

1353   Dataset 5). Then, anti-rabbit or mouse horseradish peroxidase (HRP) conjugated

1354   secondary antibodies were used and antibody-protein complexes were visualised

1355   using ECL (GE-Healthcare). Bands intensities were quantified using Fiji software. All

1356   antibodies used are listed in Supplementary Dataset 5.

1357

1358   **<u>Mouse line generation and maintenance</u>**

1359   All mouse experiments have been regulated under the Animals (Scientific

1360   Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the

1361   University of Cambridge Animal Welfare and Ethical Review Body (AWERB). All

1362   animal experiments have been performed in adult (>8 weeks-old) mice. Both female

1363   and male mice were used. The *R26Fucci2a* mouse line was generated from a cross

1364   between the previously described *R26Fucci2aR*[35] and Cre745 mouse lines (a kind gift

1365   from DJ Kleinjan, University of Edinburgh). Cre745 mice ubiquitously express Cre-

1366   recombinase under the control of the CAAG promoter[79], the resulting progeny of this

1367   cross therefore had permanently excised the STOP cassette in the *R26Fucci2aR* locus

1368   resulting in ubiquitous expression of Fucci2a. The CAAG-Cre transgene was crossed

1369   away in subsequent matings. The "knock-out first" *Tet1*^{tm1(KOMP)Wtsi} mouse line

1370   (named as *Tet1*^{hypo/hypo} line) was obtained from the International Knockout Mouse

1371   consortium (IKMC). To ensure mouse fertility the line was initially crossed with

1372   MF1 mice to generate a C57/Bl6xMF1 mixed background. All further generated mice

1373   were inbred within this line to maintain this mixed background. In order to generate

1374   the *Tet1* conditional (*Tet1*^{flx/flx}) mouse line, *Tet1*^{tm1(KOMP)Wtsi} mice were bred with a

ubiquitously expressing Flipase recombinase (*Rosa26FLPe),* taking advantage of built-in *frt* sites, leaving only *loxP* sites flanking exon 4 of *Tet1* (NM_001253857). For TET1 conditional deletion, *Tet1*$^{flx/flx}$ mice were bred with either the ubiquitous *Rosa26Cre*^{ERT2} (JAX lab, ROSA26Sor$^{tm1(cre/ERT2)Tyj}$/J) or the ductal specific *Prom1Cre*^{ERT2} Cre drivers[57]. Deletion of exon 4 was induced in 8-10 weeks old mice by 3 intraperitoneal injections of tamoxifen, performed at 48h intervals, at a dose of either 4mg or 0.2 mg/g (see specific experimental scheme for dosage) diluted in sunflower oil.

DDC treatment

For Acute DDC treatment, adult mice were transferred to wheat-free cages and fed with food supplemented with 0.1% DDC (Custom Animal diets, LLC). The diet was provided *ad libitum* for the duration of the experiment (2-5 days) or switched back to normal chow after 5 days. Mice were allowed to recover for 7 days. Chronic DDC experiments were performed by supplementing the diet with 0.1% DDC for 5-days for eight cycles, with a 3-day interval of normal diet between cycles. All mice were euthanized by exposure to CO_2, and, when required, blood was collected by cardiac puncture. Serum was then submitted for analysis at the Department of Veterinary Medicine, University of Cambridge.

P21 overexpression and DDC treatment

Lineage tracing and *Tet1* deletion in *Prom1Cre*^{ERT2}/Rosa^{IslZsGreen}/*Tet1*$^{flx-flx}$ mice was induced as described above. After one week, 7.5×10^{11} viral particles of AAV8-TBG-p21 were injected intravenously (by tail vein injection) as previously described[9]. After a week of wash out (allowing for a combined two-week wash out from tamoxifen injections), the mice were fed chow supplemented 0.1% DDC *ad libitum* for 5 days in three cycles each with 3 days of recovery in between DDC treatments. After 2 weeks recovery time after the final DDC dose, mice were culled and analysed.

Histology and immunohistochemistry

Livers and small intestines were removed and fixed in 10% neutral buffered formalin (Sigma-Aldrich) overnight at room temperature. After fixation tissues were frozen in O.C.T compound (VWR chemicals) or embedded in paraffin (Thermo Scientific) and

1408   processed for analysis. For Haematoxylin and Eosin (H&E) and pan-cytokeratin

1409   staining, 5μm paraffin embedded sections were deparaffinised by washing in Xylene

1410   followed by descending concentrations of ethanol (100%, 95%, 70% 50%). Slides

1411   were then either stained for standard H&E analysis or immunostained with a pan-

1412   cytokeratin (PCK) antibody (Supplementary Dataset 5). For the PCK

1413   immunostaining, following de-paraffination and hydration, endogenous peroxidase

1414   activity was blocked by incubating sections in 3% H_2O_2:MeOH for 15min at room

1415   temperature. Antigen retrieval was performed by incubating the sections in 800

1416   units/ul Proteinase K diluted in Tris-EDTA (pH 8) and 0.5% triton X-100 for 10min

1417   at 37°C. Sections were allowed to cool to room temperate before being blocked in

1418   blocking buffer [2% Normal goat serum, 1% Bovine serum albumin, 0.1% triton X-

1419   100 in TBS] for 1h at room temperature. Primary antibody was diluted in 1:100

1420   dilution of the blocking buffer and incubated o/n at 4C. Antibody detection was

1421   carried out using the Bright-DAB system (ImmunoLogic) following manufacturers'

1422   protocol. Sections were counterstained in haematoxylin and mounted in DPX

1423   mounting medium.

1424   When stated, 5um paraffin sections were stained with Picro-sirius Red according to

1425   manufacturer instructions (Abcam, ab150681). Fibrotic area was calculated using a

1426   Fiji Image macro developed in house.

1427

Immunofluorescence

1428

1429   Liver sections (50-100μm thick) were cut from O.C.T. embedded samples and washed

1430   in PBS twice. Sections were blocked in 1% Triton X-100 (Sigma-Aldrich), 5%

1431   DMSO (Sigma-Aldrich), 2% Donkey Serum (Sigma-Aldrich) for 16h at 4C and

1432   incubated with the primary antibody (see Supplementary Dataset 5) diluted in 0.5%

1433   Triton X-100, 1% DMSO, 2% Donkey Serum for 72h at 4C. Sections were washed

1434   thoroughly over 24h with 0.5% Triton X-100 and 1% DMSO. Appropriate

1435   fluorophore conjugated secondary antibodies were diluted in 0.5% Triton X-100, 1%

1436   DMSO and 2% Donkey Serum and incubated on sections for 48h at 4C. The sections

1437   were washed in PBS and incubated with Hoechst 33342 diluted 1:1000 in PBS for 1h

1438   at room temperature. Finally, sections were incubated in ascending glycerol

1439   concentrations (10%, 30%, 50%, 70% 90%) for 1h each and then mounted in

1440   Vectashield (Vector Laboratories). Stained sections were imaged using a Leica SP5

1441   confocal microscopy and analysed in Fiji.

1442

Code availability:

1444 All codes used are available upon request.

1445

Statistics and Reproducibility

Statistical analyses are described in detail for each panel. Briefly, statistical analyses of ChIP-qPCR, RT-qPCR, cell-culture experiments were performed using Prism 6 software. Student two tailed t-test or two ways ANOVA combined with Tukey HSD test were used according to the experiment. Statistical analyses used for identification of DMRs based on WGBS we re identified using DSS. RRHP and immunostainings were performed using R (v3.4.4). Kruskal Wallis test with Dunns multiple comparisons was used a statistical test for RRHP. Statistical analyses of immunofluorescence data were performed using Wilcoxon rank sum test. Population distributions of the proliferative ductal populations (Ki67$^+$/OPN$^+$ cells) as well as the total ductal populations (OPN$^+$) were compared between genotypes using two sided Kolmogorov-Smirnov test. Distributions were then visualised using box and whisker plots and histograms with kernel density estimate values overlaid. Histogram bin sizes were determined by splitting the total data range into 30 bins of equal size. Frequency density was then calculated by taking the number of counts within each bin and dividing it by bin size and total number of counts in the group.

For peak calling of DamID-sequencing and ChIP-sequencing experiments statistics were performed using MACS2. DE genes in the RNA-sequencing were called using Sleuth with Wald test. Statistical analyses of expression of TET1 targets were performed with one-way ANOVA followed by Tukey's multiple comparisons test. GO analyses were perfomed using DAVID 6.8. n size of the samples was indicated for each panel. No data points were removed. All experiments presented were reproducible.

1469

Data availability:

RNA, ChIP, DamID, WGBS and RRHP sequencing data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE123133.

All other data supporting the findings of this study are available from the corresponding author on reasonable request.

Supplementary datasets:

Movie1: Time lapse movie of EpCAM+ ductal cells FACS-sorted from undamaged R26Fucci2a mouse embedded in matrigel and grown in organoid culture conditions for 72h

Supplementary Dataset 1: RNA-sequencing data

Supplementary Dataset 2: WGBS and RRHP data

Supplementary Dataset 3: TET1-DamID sequencing and H3K4me3 ChIP-sequencing data

Supplementary Dataset 4: List of DE genes *in vivo* and merge with TET1 targets, WGBS and RRHP

Supplementary Dataset 5: List of antibodies, primers and siRNA sequenc

References:

70   Broutier L. *et al.* Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. *Nat Protoc* **11**, 1724-1743, doi:10.1038/nprot.2016.097 (2016).

71   Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**, 676-682, doi:10.1038/nmeth.2019 (2012).

72   Wu, H., Caffo, B., Jaffee, H. A., Irizarry, R. A. & Feinberg, A. P. Redefining CpG islands using hidden Markov models. *Biostatistics* **11**, 499-514, doi:10.1093/biostatistics/kxq005 (2010).

73   Antonica, F., Orietti, L. C., Mort, R. L. & Zernicka-Goetz, M. Concerted cell divisions in embryonic visceral endoderm guide anterior visceral endoderm migration. *Developmental biology* **450**, 132-140, doi:10.1016/j.ydbio.2019.03.016 (2019).

74   Picelli, S. *et al.* Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc* **9**, 171-181, doi:10.1038/nprot.2014.006 (2014).

75   Aloia, L. *et al.* Zrf1 is required to establish and maintain neural progenitor identity. *Genes Dev* **28**, 182-197, doi:10.1101/gad.228510.113 (2014).

76   McLean, C. Y. *et al.* GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**, 495-501, doi:10.1038/nbt.1630 (2010).

77   Stempor, P. & Ahringer, J. SeqPlots - Interactive software for exploratory data analyses, pattern discovery and visualization in genomics. *Wellcome Open Res* **1**, 14, doi:10.12688/wellcomeopenres.10004.1 (2016).

78   Marshall, O. J. & Brand, A. H. damidseq_pipeline: an automated pipeline for processing DamID sequencing datasets. *Bioinformatics* **31**, 3371-3373, doi:10.1093/bioinformatics/btv386 (2015).

79   Kleinjan, D. A. *et al.* Long-range downstream enhancers are essential for Pax6 expression. *Developmental biology* **299**, 563-581, doi:10.1016/j.ydbio.2006.08.060 (2006).

Figure 1_Aloia et al.

a

b

c

d

e

Figure 2_Aloia et al.

a

mouse → FACS → ductal cell → Time RNA collection
0h 12h 24h 48h // 6 days → organoid

Time point vs 0h

n DE genes
0h vs 12h, 0h vs 24h, 0h vs h48, 0h vs Org

b

1 n=996
2 n=955
3 n=338
4 n=597
5 n=1278
6 n=150
7 n=1770
8 n=690
9 n=147
10 n=659

0h 12h 24h 48h organoid

+1.5 0 −1.5
Z score

c

Cluster: transcription, cell growth, protein ubiquitination, immune response, response to wound, mitosis, cell cycle, cell division, DNA damage response, small GTPase transduction, cytoskeleton processes, **chromatin modification**, **chromatin organisation**, neuron development, apoptotic process

1, 2, 3, 4, 5, 6, 7, 8, 9, 10

35 25 15 05 NS
−ln (p value)

d

Tet1
Tet2
Tet3
mki67
Lgr5
Trop2
Epcam
Sox9
Krt19
Prom1

0h 12h 24h 48h organoid

+1.5 0 −1.5
Z score

e

TET methylcytosine dioxygenases
fold change vs 0h
Tet1, Tet2, Tet3
0h 12h 24h 48h organoid

SWI/SNF chromatin remodelling
Arid1b, Arid5b, Baf155, Smarca4
0h 12h 24h 48h organoid

HDAC/Polycomb histone modifiers
Hdac2, Hdac1, Cbx6
0h 12h 24h 48h organoid

f

mouse
DDC diet
Day 0 2 3 5
FACS IF IF FACS IF FACS IF
ductal cell (RNA) ductal cell (RNA) ductal cell (RNA)

g

Undamaged, DDC d2, DDC d3, DDC d5
OPN, Ki67, Hoechst

% Ki67+/OPN+
0.4 0.6 4.5 19.1
Undamaged d2 d3 d5
DDC

h

In vitro organoids   In vivo DDC
6472   1108   444
Representation Factor 1.7
p value< 2.2 e^−229

Cluster: GPI anchoring, multi-protein assembly, **chromatin modification**, cell-cycle, stress response, transcription, oxidative phosphorylation, mesoderm differentiation, angiogenesis, circadian rhythm, rRNA processing

1, 2, 3, 4, 5, 6, 7

>20 15 10 05 NS
−ln (p value)

i

In vitro organoids   In vivo DDC

1 n=183
2 n=276
3 n=260
4 n=69
5 n=76
6 n=154
7 n=90

Bmp1, Hdac7, Pcgf2, Sox4, Tcf3, Ccnb1, Cdk1, Dnmt1, Erbb2, Foxa3, Uhrf1, Atf3, Cebpa, Fosb, Idh1, Plekhg2, Ctgf, Rras, Ncor2, Sulf2, Wnt7a, Bambi, Jun, Klf2

0h 12h 24h 48h organoid   Undamaged DDC d3 DDC d5

+1.5 0 −1.5   +1.0 0 −1.0
Z score   Z score

Figure 3_Aloia et al.

Figure 4_Aloia et al.

Figure 5_Aloia et al.

Figure 6_Aloia et al.

a

KEGG pathways 577 genes
TET1 targets/5hmC *in vivo*

Pathways (top to bottom): mTOR, Insulin, ErbB, AMPK, Estrogen, YAP/Hippo, MAPK

x-axis: -ln (p value), from 0 to 10

b

TET1 ChIP liver organoids

y-axis: % of input (0.0 to 1.0)

x-axis genes: Egfr, Ptprs, Foxo3, Etv5, Socs2, Atf4, Jun, Gadd45b, Ctgf, Nf2, Wwtr1, Tead1, Jak1, Ptk2

c

y-axis: fold change (0.0625 to 8)

Legend: Ctrl, Tet1 cKO

x-axis genes: Egfr, Ptprs, Foxo3, Etv5, Socs2, Atf4, Jun, Gadd45b, Ctgf, Nf2, Wwtr1, Tead1

d

y-axis: fold change (0.0 to 2.5)

Legend: WT, $Tet1^{hypo/hypo}$, *hypo-OE*

x-axis genes: Gadd45b, Ctgf, Nf2, WWtr1, Tead1

e

FACS → ductal cell → Analysis TET1 ChIP (18h) → 6 days → organoid

y-axis: % of input (0.0 to 1.0)

x-axis genes: Egfr, Foxo3, Jun, Gadd45b, Ctgf, Wwtr1, Tead1

f

FACS → ductal cell → 0h / 18h / 48h → Analysis → 6 days → organoid

y-axis: Organoid formation (%) (0 to 25)

0-18 hrs | 18-48 hrs

x-axis: DMSO, 100nM Gefitinib (EGFRi), 25nm PD0325901 (MEKi), 10nmVerteporfin (YAPi)

DMSO, EGFRi, MEKi, YAPi (organoid images)

Figure 7_Aloia et al.

a

DDC diet

Day 0 → 5

WT — *Tet1^{Hypo/Hypo}*

OPN
Ki67
Hoechst

Undamaged (day 0): PV, PV

DDC Damage (day 5): PV, PV

% Proliferating ductal cells (Ki67+/OPN+)

WT
Tet1^{hypo/hypo}

p=0.64

***

Undamaged — DDC

b

Undamaged (day 0)

WT
Tet1^{Hypo/Hypo}

Frequency Density (count/ bin width/ total)

DDC Damage (day 5)

% Proliferating ductal cells (Ki67+/OPN+)

c

8x d5 DCC

DDC DDC DDC DDC DDC DDC DDC DDC

3 months Recovery
normal chow

Sirius Red staining (**Fibrosis**)

Undamaged — Recovery — Magnification

WT

Tet1^{Hypo/Hypo}

d

WT

Tet1^{Hypo/Hypo}

Area of Collagen (mm²)

p=0.496725
NS

p=0.025821
*

Undamaged — Chronic Damage

Figure 8_Aloia et al.

Aloia_Extended Data Figure 01

a

b

c

Aloia_Extended Data Figure 02

a

Between time points

b

**Epigenetic regulators
(383 genes)**

+1.5   0   −1.5

Z score

c

+1.0   0   −1.0

Z score

d

e

Gene Ontology Categories

-ln (p value)

Aloia_Extended Data Figure 03

Aloia_Extended Data Figure 04

a

WGBS Unique Mapped Reads

N unique mapped reads
(800,000 / 600,000 / 400,000 / 200,000)

Undamaged, DDC day 3, DDC day 5

b

Bisulfite conversion rate

% conversion rate C-T
(100.0 / 99.5 / 99.0 / 98.5 / 98.0)

Undamaged, DDC day 3, DDC day 5

c

CpG count (merged n=2)

	Und. (n=2)	d3 (n=2)	d5 (n=2)	Shared
All	29,328,807	28,317,933	29,776,416	
≥3 cov	22,347,108	18,723,512	23,844,822	18,456,635

d

Spearman's correlation score (WGBS)

	DDC day 3	Undamaged	DDC day 5
DDC day 3	1.00	0.48	0.48
Undamaged	0.48	1.00	0.51
DDC day 5	0.48	0.51	1.00

Scores (1 / 0.9 / 0.8 / 0.7 / 0.6 / 0.5)

e

Total DMRs (black), Gene body (orange), TSS (-2 to +1kbp) (red)

Number of DMR
(1,400 / 1,050 / 750 / 350 / 0)

d3 vs undamaged, d5 vs undamaged, d5 vs d3

f

DMR length

DMR length [bp]
(800 / 600 / 400 / 200 / 0)

d3 vs undamaged (119), d5 vs undamaged (114), d5 vs d3 (124)

g

Loss / Gain

density (2 / 1 / 0)

d3 vs Undamaged
d5 vs Undamaged
d5 vs d3

Difference in DMR mCpG (-1.0 / -0.5 / 0.0 / 0.5 / 1.0)

h

Up-regulated genes *in vivo*

TET1 targets — WGBS Loss
145 | 55 | 282

TEt1 targets — WGBS Gain
137 | 63 | 286

Ptp4a3
Stk11p
Mapkapk3
Plau
L3mbtl3
Trip13
Rbp1
Cks1b
E2f1
Idh1
Fabp5
Pole2
Map3k9
Socs2
Ccnb1
Rasal1
Sulf2
Pmaip1
Ddr1
Pold1
Dnmt1

Undamaged, DDC day 3, DDC day 5

Ctgf
Slc36a4
Slc38a1
Ap1ar
Cdk1
Ptprs
Abcc4
Egfr
Itgav
Itga2
Ccna2
Mmp14
Mmp7
Abca7
Plekhg2
S100a11
E2f3

Undamaged, DDC day 3, DDC day 5

+1.0 — -1.0
Z score (gene expression)

Aloia_Extended Data Figure 05

a

WT — DDC diet — Day 0, 3, 5

DDC-damage: Undamaged, day 3, day 5
5hmC / DAPI

5hmC/DAPI — Undamaged, DDC day 3 ***, DDC day 5 ***

b

cKO β1 integrin hepatocytes — (7 days) DDC diet — (14 days) Recovery — Undamaged, 1, 7, 14

Recovery: Undamaged, day 1, day 7, day 14
5hmC DAPI

5hmC/DAPI vs Undamaged — Undamaged, day 1, day 7, day 14, Recovery

c

WT — 3D culture — 0, 24h, 48h

0h, 3D Culture 24h, 48h
5hmC DAPI

5hmC/DAPI vs 0h — 0h, 24h ***, 48h ***

d

Number of 5hmC sites (RRHP)

DDC day 5 n=567,211: 61,075
Undamaged n=536,972: 34,778
DDC day 3 n=552,746: 48,266
36,396 / 38,692 / 431,058 / 34,740

e

Number of TSS — Undamaged, DDC day 3, DDC day 5

n of unique gain 5hmC: ≥10, 9, 8, 7, 6, 5, 4

f

WGBS CGI outside TSS — % of mCpG — Undamaged, DDC day 3, DDC day 5

RRHP CGI outside TSS — 5hmC count — Undamaged, DDC day 3, DDC day 5

g

GO Biological processes

	Transcription	DNA damage response	Cell cycle	Cell migration	Apoptosis	Chromatin modification	Development
Cluster 2							
Cluster 3							
Cluster 4							
Cluster 6							

-ln (pvalue): NS 6 12

h

5hmC genes: 3497, 84, Down-regulated in vivo: 436

Z score +1.0, 0, −1.0

Klf2, Cbx4, Sirt1, Jun, Fosb, Bambi, Atf3, Cebpa, Ring1

Undamaged, DDC day 3, DDC day 5

Aloia_Extended Data Figure 06

a

b TET1 DamID-seq / H3K4me3 ChIP-seq — Common peaks (TET1 and H3Kme3), Tet1-specific peaks

c TET1-Dam peak distribution
- Promoter (<=1kb) (49.61%)
- Promoter (1−2kb) (5.33%)
- 5' UTR (0.67%)
- 3' UTR (1.35%)
- 1st Exon (0.71%)
- Other Exon (3.27%)
- 1st Intron (8.74%)
- Other Intron (9.47%)
- Downstream (<=300) (0.63%)
- Distal Intergenic (20.23%)

d GO TET1 targets biological Processes

e *Lgr5 genomic loci* — hMeDIP, MeDIP

f TET1 ChIP, *Lgr5* mRNA

g *Trop2*, *Sulf2*, *Cyp3a11*, *G6pc*

# Aloia_Extended Data Figure 07

a

Aloia_Extended Data Figure 08

a Adult mouse weight (undamaged)

p= 0.82
p= 1.00

- WT
- Tet1$^{Hypo/+}$
- Tet1$^{Hypo/Hypo}$

b Relative mouse weight during damage and recovery

DDC Diet | Recovery

WT
Tet1$^{Hypo/+}$
Tet1$^{Hypo/Hypo}$

c Intestine 50 weeks

WT | Tet1$^{hypo/hypo}$

Undamaged

d Intestine 10 weeks

WT | Tet1$^{hypo/hypo}$

DDC Damaged (day 5)

e % Proliferating ductal cells (Ki67+/OPN+)

p=0.003
**

Recovery

f OPN population (# of OPN+ cells)

WT
Tet1$^{hypo/hypo}$

p=0.57
p=0.022 *
p=7.5x10^{-9} ***

Undamaged | DDC | Recovery

g Frequency Density (count/ bin width/ total)

Undamaged (day 0)

WT
Tet1$^{Hypo/Hypo}$

Recovery (day 12)

Ductal population (# of OPN+ cells)

h

WT | Tet1$^{hypo/hypo}$

Undamaged (day 0)

Recovery (day 12)

i

Lgr5 mRNA

WT
Tet1$^{Hypo/Hypo}$

mRNA levels relative to *Hprt*

p= 0.0017
**

Tet1 mRNA

p= 0.0332
*
p= 0.0047
**

TET1 ChIP

% of input

p= 0.0149
*

Undamaged | DDC day 5

hMeDIP

p= 0.0128
*

Undamaged | DDC day 5

Aloia_Extended Data Figure 09

a

$Tet1^{flx/flx}$

E3 — E4 — E5

$Rosa^{lslZsGreen}$

Rosa26 — Stop — **ZsGreen**

$Prom1Cre^{ERT2}$

Prom1 — CreERT2

b Tamoxifen induction (undamaged)

$Prom1^{Tet1\ WT/ZsGreen}$

$Prom1^{\Delta Tet1/ZsGreen}$

Hoechst ZsGreen | ZsGreen OPN | Merge

c Uninduced

$Prom1^{Tet1\ WT/ZsGreen}$

Hoechst ZsGreen OPN | ZsGreen HNF4 | Merge

d *Tet1* expression

mRNA relative to *Hprt*

p= 0.000227

$Prom1^{Tet1\ WT/ZsGreen}$ $Prom1^{\Delta Tet1/ZsGreen}$ ***

e P21

$Prom1^{Tet1WT}$

$Prom1^{\Delta Tet1}$

Non-Infected Control ($Prom1^{Tet1WT}$)

f Mouse Weight Time Course

Weight (%)

$Prom1^{Tet1WT}$
$Prom1^{\Delta Tet1}$

TAM injections (0.2 mg/g)   AAV8-TBG-p21

DDC   Normal Chow

DDC | DDC | DDC | Recovery

Day

g TET1 ChIP DDC day 5

% of input

Egfr Foxo3 Jun Ctgf Gadd45b Wwtr1 Tead1

ND ND ND

h

Egfr p= 0.01295 *

Ctgf p= 0.03360 *

Wwtr1 p= 0.00002 ***

Tet1 p= 0.01463 *

fold change vs WT undamaged

Undamaged   DDC day 5

$Prom1^{Tet1\ WT/ZsGreen}$
$Prom1^{\Delta Tet1/ZsGreen}$